[
    {
        "parameters": {
            "embedding model": "BAAI/bge-small-en-v1.5",
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 128,
            "overlap": 25,
            "top_k": 5,
            "max new tokens": 190,
            "re-ranking": 0,
            "top_n": 0
        },
        "queries": [
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the retrospective observational studies comparing carbapenems with non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, for the treatment of 3GCephRE infections?",
            "What was the finding of the studies evaluating cephamycins (cefmetazole or flomoxef) versus carbapenems for the treatment of 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated UTI?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "None of the studies found a significant difference in outcomes between carbapenems and non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, although some studies reported a trend in favour of carbapenems or non-carbapenem-sparing antibiotics, but the evidence was limited by small sample sizes and residual differences between groups despite adjustment.",
            "The studies found no significant difference in mortality between cephamycins and carbapenems, except for one study that found an association between flomoxef therapy and mortality when the MIC was elevated within the susceptible range, but the overall certainty of the evidence was very low due to limitations in study design and sample size.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found no significant differences in clinical cure and microbiological outcomes between carbapenems and non-carbapenem antibiotics, including BLBLI, which achieved similar outcomes to carbapenems, with moderate-certainty evidence.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study design, such as randomized controlled trials (RCTs), observational studies, or systematic reviews. RCTs are considered the gold standard for evaluating the efficacy and safety of new treatments, while observational studies can provide valuable real-world data on how a treatment is used in clinical practice.\n2. Clinical guidelines: Clinical guidelines provide evidence-based recommendations for the diagnosis, prevention, and treatment",
                "Retrospective observational studies have compared the use of carbapenems with non-carbapenem antibiotics, including cephalosporins, quinolones, and aminoglycosides, for the treatment of infections caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). The findings of these studies have suggested that carbapenems are generally more effective in achieving microbiological and clinical cure compared to non-carbapenem antibiotics.\n\nHowever, it is important to note that these studies have several limitations, including selection bias, lack of standardized definitions for infection and outcome, and potential confounding factors. Additionally, the emergence of carbapenem-resistant bacteria, such as carbapenem-resistant Enterobacterales (CRE), has challenged the use of carb",
                "Several studies have compared the effectiveness and safety of cephamycins (cefmetazole or flomoxef) and carbapenems for the treatment of 3rd generation cephalosporin-resistant bloodstream infections (3GCephRE BSIs). Here are some key findings from these studies:\n\n1. Efficacy: The studies suggest that both cephamycins and carbapenems have similar efficacy in the treatment of 3GCephRE BSIs. However, some studies have shown that carbapenems may have a slightly higher success rate in achieving microbiological and clinical cure.\n2. Safety: Cephamycins are generally considered to be less toxic than carbapenems. However, they may cause more frequent and severe diarrhea compared to carbapenems.\n3. Resistance: The emergence of resistance",
                "Several studies have compared the effectiveness and safety of cephamycins (cefotetan and ceftriaxone) and cefepime to carbapenems (imipenem and meropenem) in the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase producing Enterobacteriaceae (3GCephre).\n\nA systematic review and meta-analysis of 12 randomized controlled trials (RCTs) by Zhang et al. (2018) found that cephamycins and cefepime were non-inferior to carbapenems in terms of clinical cure rate, microbiological eradication rate, and adverse events. However, subgroup analysis suggested that cefepime might be superior to carbapenems in achieving microbiological eradication in patients with severe",
                "Retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated urinary tract infections (UTIs) have yielded conflicting results. Some studies suggest that carbapenems may be more effective in achieving microbiological and clinical cure, particularly in cases of multidrug-resistant pathogens or complicated UTIs caused by Gram-negative bacteria. However, other studies have not shown significant differences in outcomes between carbapenems and non-carbapenem antibiotics.\n\nOne meta-analysis of 12 retrospective studies found that carbapenems were associated with a higher microbiological cure rate (OR 1.35, 95% CI 1.05-1.73) and a lower risk of treatment failure (OR 0.58, 95% C",
                "Several randomized controlled trials (RCTs) have evaluated the effectiveness of various antibiotics for the treatment of intra-abdominal infections (IAIs) caused by third-generation cephalosporin-resistant Enterobacterales (3GCRE). Here are some key findings from these studies:\n\n1. Carbapenems: Carbapenems, such as imipenem, meropenem, and ertapenem, have shown superiority over older antibiotics like ampicillin-sulbactam and cefotaxime in the treatment of 3GCRE-caused IAIs. Carbapenems have a broader spectrum of activity against Gram-negative bacteria, including 3GCRE, and are associated with higher clinical cure rates and lower mortality rates.\n2. Fluoroquinolones",
                "Meropenem-vaborbactam (MVB) is a carbapenem-beta-lactamase inhibitor combination antibiotic that has shown activity against certain carbapenem-resistant Enterobacterales (CRE), including those producing NDM-1 and OXA-48-type carbapenemases. The advantage of MVB over best available treatment for susceptible CRE is supported by several studies with varying levels of evidence.\n\n1. Randomized Controlled Trials (RCTs): A few small RCTs have compared MVB to other antibiotics for the treatment of infections caused by susceptible CRE. For example, a multicenter, randomized, non-inferiority trial (NCT02929593) compared MVB to imipenem-relebactam",
                "The comparative effectiveness and safety of aminoglycosides versus tigecycline for the treatment of complex urinary tract infections (cUTI) have been studied in several clinical trials. However, the evidence is not clear-cut, and the results are inconsistent.\n\nA systematic review and meta-analysis of 13 randomized controlled trials (RCTs) published in the Cochrane Database of Systematic Reviews in 2019 found that there was no significant difference in the overall response rate, mortality, or adverse events between aminoglycosides and tigecycline for the treatment of cUTI. However, the analysis suggested that aminoglycosides may be more effective in eradicating Gram-negative pathogens, particularly Pseudomonas aeruginosa, compared to tigecycline.\n\nAnother meta-",
                "Plazomicin and colistin are both antibiotics used in the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), but the evidence comparing the two drugs in terms of efficacy, safety, and optimal use is still evolving.\n\nPlazomicin is a new generation aminoglycoside with improved activity against CRE compared to older aminoglycosides. A phase 3 clinical trial, named FORTA (Forta-I and Forta-II), evaluated the efficacy and safety of plazomicin compared to meropenem or colistin in the treatment of complicated urinary tract infections (cUTI) and bloodstream infections (BSI) caused by CRE. The results of this trial showed that plazomicin was non-inferior to meropenem and colist",
                "Several studies have investigated the difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with infections caused by Carbapenem-resistant Enterobacterales (CRE), including those caused by carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa. The results of these studies have been inconsistent.\n\nSome studies have reported no significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy. For example, a retrospective study of 112 patients with CRE infections published in the Journal of Antimicrobial Chemotherapy found no significant difference in 28-day mortality between the two groups (18.2%",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE), including Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is still emerging, and the optimal approach is not yet fully established.\n\nSeveral studies have investigated the efficacy and safety of cefiderocol monotherapy compared to combination therapy in the treatment of CRE infections. Here are some key studies:\n\n1. SAVANNA Trial: The SAVANNA (CEFIDERCOL vs. COLISTIN/IMPIPENEM for the Treatment of Carbapenem-resistant Enterobacteri",
                "I apologize for any confusion, but I cannot provide you with the specific results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections as there seems to be no published study with that exact title and inclusion criteria.\n\nHowever, there have been several studies investigating the effectiveness and safety of ceftolozane-tazobactam compared to polymyxins or aminoglycosides in the treatment of monomicrobial MDR/XDR P. aeruginosa infections.\n\nA systematic review and meta-analysis of 11 studies published in the Journal of Antimicrobial Chemotherapy in 2019 found that ceftolozane-tazobact",
                "CRPA (Carbapenem-resistant Pseudomonas aeruginosa) infections can be challenging to treat due to the resistance of the bacteria to many antibiotics. Polymyxins, aminoglycosides, and fosfomycin are commonly used antibiotics for the treatment of CRPA infections.\n\nPolymyxins (colistin and polymyxin E) are considered the first-line antibiotics for severe CRPA infections due to their gram-negative bactericidal activity. Polymyxins bind to the lipid A component of the bacterial cell wall, disrupting the membrane and leading to bacterial death. However, polymyxins can cause nephrotoxicity and neurotoxicity, which can limit their use.\n\nAminoglycosides (gentamicin, to",
                "For patients with CRAB (Clostridioides difficile-related complications, including severe colitis, fulminant colitis, megacolon, and toxic megacolon) who are susceptible to sulbactam and have healthcare-associated pneumonia (HAP) or ventilator-associated pneumonia (VAP), the suggested treatment may depend on the severity of the infection and the patient's overall condition.\n\nFirst-line antibiotic therapy for HAP/VAP caused by Clostridioides difficile typically includes metronidazole, vancomycin, or fidaxomicin for the treatment of the underlying C. difficile infection. However, these antibiotics may not be effective against HAP/VAP complications.\n\nIn such cases, empiric antimicrobial therapy for H",
                "Cefiderocol is a siderophore cephalosporin antibiotic that is approved for the treatment of complicated intra-abdominal infections, including those caused by susceptible Gram-negative bacteria. CRAB (community-acquired or nosocomial-acquired, recurrent or persistent, intra-abdominal infections) is a specific type of intra-abdominal infection.\n\nSeveral studies have evaluated the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections. Here are some key findings:\n\n1. A randomized, double-blind, multicenter study compared cefiderocol to meropenem in the treatment of complicated intra-abdominal infections, including CRAB. The study showed that cefiderocol was non-inferior to meropenem",
                "Polymyxin-carbapenem combination therapy has been studied as a potential treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections based on the synergistic effect of both antibiotics. Here are some observational studies that have investigated the effectiveness of this combination therapy for CRAB infections:\n\n1. A retrospective study by Liu et al. (2018) analyzed the medical records of 112 patients with CRAB infections who received polymyxin-carbapenem combination therapy. The study reported a 91.1% overall response rate, with a 78.6% success rate in eradicating the infection. The authors concluded that polymyxin-carbapenem combination therapy is effective in treating CRAB infections.\n\n2.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections are a significant challenge in clinical microbiology due to the increasing resistance of these bacteria to commonly used antibiotics. Here are some general principles for antibiotic treatment in patients with CR-GNB infections:\n\n1. Identify the specific CR-GNB causing the infection through microbiological culture and susceptibility testing. This information is crucial for selecting the most effective antibiotic.\n2. Choose an antibiotic with in vitro activity against the identified CR-GNB. This may include polymyxins (such as polymyxin B or E), aminoglycosides (such as amikacin or gentamicin), tigecycline, or other novel antibiotics.\n3. Consider the site of infection and the patient's clinical condition when",
                "Patients undergoing colorectal and liver transplant surgery require careful preoperative evaluation due to the complex nature of these procedures and the potential for complications. Here are some suggested screening approaches for these patients:\n\n1. Colorectal Transplant Surgery:\n- Preoperative assessment should include a thorough history and physical examination, with a focus on the gastrointestinal system.\n- Laboratory tests: Complete blood count, coagulation studies, electrolytes, liver function tests, and carcinoembryonic antigen (CEA) level.\n- Imaging studies: Colonoscopy or flexible sigmoidoscopy with biopsy if indicated, abdominal and pelvic CT or MRI to evaluate for any unsuspected lesions or metastases.\n- Infection screening: Hepatitis B and C serology, human immun",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Resistive-Escherichia coli (ESCR-E) undergoing colorectal surgery is not clear-cut and depends on several factors.\n\nThe European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Surgical Research Group (ESRG) published guidelines in 2017 recommending PAP for patients with active infections or colonization with multidrug-resistant organisms (including ESCR-E) if the infection is likely to spread during surgery. However, for asymptomatic colonization, the benefit of PAP is less clear.\n\nThe Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of",
                "Extensively drug-resistant Enterococci (ESCR-E) and extensively drug-resistant Pseudomonas aeruginosa (ESCR-PA) are bacteria that have developed resistance to most or all available antibiotics. The treatment of infections caused by these bacteria is a challenge, and the use of last-resort antibiotics should be reserved for specific cases.\n\nThe European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Society of Intensive Care Medicine and Anesthesiology (ESICM) have published guidelines on the management of infections caused by ESCR-E and ESCR-PA. According to these guidelines, the following antibiotics should be reserved for the treatment of infections caused by extensively resistant bacteria and not used routinely:\n\n1. Polymyxins",
                "Research protocols investigating the impact of targeted PAP (pneumococcal and other encapsulated bacteria prevention using antibiotics) in reducing post-transplant infections among Extended-Spectrum Cephalosporin Resistant-Enterococcus (ESCR-E) colonized Solid Organ Transplant (SOT) candidates should include the following elements:\n\n1. Study Design: The study design should be clearly stated, including the type of study (interventional, observational, etc.), the study population, and the study setting.\n2. Objectives: The study objectives should be clearly stated, including the primary and secondary endpoints.\n3. Inclusion and Exclusion Criteria: The inclusion and exclusion criteria should be clearly defined to ensure that the study population is appropriate for the research question.\n4. Intervention: The intervention should be clearly described, including the",
                "Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. The goal of PAP is to reduce the risk of surgical site infections (SSIs). In patients colonized with CRE, the risk of developing SSIs is increased due to the potential for carrying antibiotic-resistant bacteria. Therefore, targeted PAP with antibiotics effective against CRE can help reduce the risk of SSIs in these patients. However, the specific antibiotic choice and dosing regimen should be determined based on local guidelines and patient-specific factors, such as the type of surgery and patient allergies. It is also important to note that PAP should not replace the need for strict infection control measures to prevent the spread of CRE.",
                "Screening SOT (solid organ transplant) recipients for CRAB (chronic rejection, acute rejection, banff lesions) before surgery involves a comprehensive evaluation to assess the current status of the transplanted organ and the overall health of the recipient. Here are some good practices for screening SOT recipients for CRAB before surgery:\n\n1. Review of medical history: A thorough review of the recipient's medical history, including details of the transplant procedure, immunosuppressive therapy, and previous episodes of rejection, if any.\n\n2. Laboratory tests: A complete blood count (CBC), serum creatinine, liver function tests, and immunosuppressive drug levels should be checked.\n\n3. Imaging studies: Imaging studies such as ultrasound, CT scan, or MRI may be required to assess the size, function",
                "To investigate CRAB (Candida auris-related bloodstream infections) colonization and targeted PAP (positive blood culture identification and antimicrobial stewardship), the following types of clinical trials could be suggested:\n\n1. Prospective observational studies: These studies can be used to assess the prevalence and incidence of CRAB colonization in different patient populations and settings. They can also evaluate the effectiveness of targeted PAP in identifying CRAB infections and guiding antimicrobial therapy.\n2. Randomized controlled trials (RCTs): RCTs can be used to evaluate the efficacy and safety of interventions aimed at reducing CRAB colonization and preventing CRAB infections. For example, studies could investigate the use of decolonization protocols, such as chlorhexidine bathing or antifungal agents, to reduce CRAB",
                "In transplant surgery other than renal transplants, the suggested duration of post-anesthesia care unit (PACU) or post-operative recovery varies depending on the specific type of surgery and the individual patient's condition. Here are some general guidelines for some common non-renal transplant surgeries:\n\n1. Liver transplant: Patients are typically monitored in the ICU for 1-2 days and in the PACU for 1-2 days after liver transplant surgery.\n2. Heart transplant: Patients are typically monitored in the ICU for 1-2 weeks and in the PACU for 1-2 days after heart transplant surgery.\n3. Lung transplant: Patients are typically monitored in the ICU for 3-7 days and in the PACU for 1-2",
                "MDR-GNB (Multidrug-resistant Gram-negative bacteria) infections are a significant concern in solid organ transplant (SOT) recipients due to their increased susceptibility to infections and the potential for antibiotic resistance. The risk of MDR-GNB infections in SOT recipients varies depending on several factors, including the type of transplant, the underlying condition of the patient, and the exposure to healthcare environments.\n\nAccording to a systematic review and meta-analysis published in the Journal of Infection, the pooled incidence of MDR-GNB infections in SOT recipients was reported to be around 5-10%. However, the incidence can be higher in certain patient populations, such as those undergoing kidney transplantation or those with pre-existing conditions like diabetes or cystic fibrosis.\n\nMDR-GNB",
                "The identification of fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is important to reduce the risk of post-biopsy infections and potential development of antibiotic-resistant bacteria. Here are some suggested approaches to identify FQR-E carriers:\n\n1. Pre-biopsy urine culture: Obtain a clean-catch urine sample from the patient before the biopsy procedure. Culture the urine for Enterobacteriaceae and perform antimicrobial susceptibility testing, including fluoroquinolones. If the urine culture grows FQR-E, consider alternative antibiotic prophylaxis for the biopsy procedure.\n\n2. Rectal swab culture: Obtain a rectal sw",
                "A randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (Prostate Antigen Precipitation) versus culture-based PAP (Prostate Specific Antigen Prostatectomy) in patients undergoing Transrectal Ultrasound-Guided Prostate Biopsy (TRUSPB), particularly in fluoroquinolone-resistant (FQR) carriers, would provide data on the diagnostic accuracy and effectiveness of each method in detecting prostate cancer in this specific population.\n\nHowever, the outcome of such a trial would depend on the specific results of the study. Some possible outcomes could be:\n\n1. Ciprofloxacin PAP is more effective than culture-based PAP in detecting prostate cancer in FQR carriers. This could be due to the ability of ciproflo",
                "Urinary colonization with MDR-GNB has been identified as a risk factor for postoperative infections in patients undergoing urologic surgery. MDR-GNB are bacteria that are resistant to multiple antibiotics, making infections caused by these bacteria more difficult to treat.\n\nStudies have shown that the presence of MDR-GNB in urine samples obtained before urologic surgery is associated with an increased risk of postoperative infections. For example, a study published in the Journal of Urology found that patients with preoperative urinary colonization with MDR-GNB were more likely to develop postoperative infections than patients without colonization.\n\nThe mechanism by which urinary colonization with MDR-GNB increases the risk of postoperative infections is not fully understood, but it is believed to be related to the fact that these bacteria can establish",
                "Reducing surgical site infections (SSIs) requires a comprehensive approach that addresses various factors before, during, and after surgery. Here are some key elements of a comprehensive approach to reducing SSIs:\n\n1. Preoperative preparation:\n   a. Proper patient selection and optimization\n   b. Timely and appropriate antibiotic prophylaxis\n   c. Management of comorbid conditions\n   d. Proper hair removal and skin preparation\n\n2. Operating room environment:\n   a. Proper temperature and ventilation\n   b. Use of sterile equipment and instruments\n   c. Proper use of surgical drapes and gowns\n   d. Surgical team education and training\n\n3. Surgical technique:\n   a. Proper surgical site preparation and sterile technique\n   b. Use of closed-system insufflation devices during",
                "Standard Operating Procedures (SOPs) for sampling site techniques and microbiological methods are essential to ensure consistency, accuracy, and reliability in the collection and analysis of microbiological samples. Here are some recommended practices for developing SOPs in these areas:\n\n1. Sampling Site Techniques:\n\na. Define the sampling site and selection criteria.\nb. Establish a schedule for sampling.\nc. Describe the equipment required for sampling, such as sterile containers, sampling devices, and personal protective equipment.\nd. Outline the steps for collecting samples, including the number of samples to be taken, the method of collection, and the handling of the samples before transport to the laboratory.\ne. Provide instructions for documenting the sampling event, including recording the date, time, location, and environmental conditions.\nf. Establish procedures for dealing with contaminated or non-",
                "When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered to optimize the effectiveness of the antibiotic prophylaxis and minimize the risk of developing antibiotic resistance or adverse effects. Some of these factors include:\n\n1. Type and duration of the surgical procedure: The choice of antibiotic and the duration of administration should be based on the type and duration of the surgical procedure. For example, for clean-contaminated or contaminated procedures, longer durations of antibiotic administration may be required.\n2. Risk of CRE infection: The risk of CRE infection should be assessed based on the patient's medical history, comorbidities, and the prevalence of CRE in the hospital or community. Pat",
                "Colonization status refers to the presence of potentially harmful bacteria in the gastrointestinal tract that are not normally present in the body of an individual. In the context of solid organ transplantation (SOT), it is important to know the colonization status of a patient for several reasons:\n\n1. Infection risk: Patients undergoing SOT are at increased risk for infections due to the suppression of their immune system after transplantation. Colonized bacteria, particularly those that are multidrug-resistant, can cause serious infections, leading to complications and even death.\n2. Antibiotic prophylaxis: Knowing the colonization status of a patient can help guide the use of antibiotic prophylaxis to prevent infections caused by these bacteria. For example, patients who are colonized with certain bacteria may benefit from targeted antibiotic therapy before and"
            ],
            "additional prompt / no context": [
                "The evidence on the treatment of infections caused by third-generation cephalosporin-resistant bacteria (3GCRE) is organized through numerous studies, meta-analyses, and guidelines. These sources provide evidence on the effectiveness and safety of various antibiotics, including carbapenems, aminoglycosides, and polymyxins, among others. The Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) publish guidelines on the diagnosis and treatment of infections caused by 3GCRE. Additionally, the Centers for Disease Control and Prevention (CDC) provides recommendations based on the latest scientific evidence. It is important to note that the most effective treatment depends on the specific type and location of the infection, as well as the susceptibility patterns of the bacteria.",
                "Retrospective observational studies have shown that carbapenems are more effective than non-carbapenem antibiotics, including cephalosporins, quinolones, and aminoglycosides, in treating 3rd generation cephalosporin-resistant infections (3GCephRE). Carbapenems have a higher success rate in achieving microbiological and clinical cure. However, they are associated with higher costs and potential side effects. The choice of antibiotic should consider the specific infection, patient factors, and local resistance patterns.",
                "The studies comparing cephamycins (cefmetazole or flomoxef) to carbapenems for the treatment of 3GCephalosporin-resistant bloodstream infections (BSIs) have shown that cephamycins are less effective than carbapenems in terms of microbiological cure and clinical response. However, they may still be considered as an option in certain situations, such as when other alternatives are limited and the patient's condition is stable. It is important to note that individual patient outcomes may vary and that consultation with an infectious disease specialist is recommended for optimal management.",
                "The studies suggest that cephamycins and cefepime are comparable to carbapenems in terms of clinical cure rates for pyelonephritis caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). However, higher resistance rates to cephamycins and cefepime may require larger doses or alternative agents for effective treatment.",
                "Retrospective studies have shown that carbapenems are more effective than non-carbapenem antibiotics in treating complicated urinary tract infections (UTIs), particularly in cases of multidrug-resistant bacteria. However, carbapenems are associated with higher costs and potential side effects. The choice between carbapenems and non-carbapenem antibiotics depends on the specific clinical situation and local antibiotic resistance patterns.",
                "The RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3rd-generation cephalosporin-resistant (3GCephR) bacteria have shown that:\n\n1. Carbapenems (imipenem, meropenem) are effective in treating 3GCephR-IAI.\n2. Aminoglycosides (gentamicin, amikacin) in combination with beta-lactams (piperacillin-tazobactam, ceftriaxone-gentamicin) can be an alternative for carbapenem-unavailable settings.\n3. Fluoroquinolones (ciprofloxacin, levofloxacin) have shown variable efficacy and are generally less preferred due to resistance concerns",
                "The level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible Carbapenem-resistant Enterobacterales (CRE) is high, based on numerous clinical studies demonstrating superior clinical outcomes, such as higher microbiological and clinical cure rates, and reduced mortality. However, it's important to note that resistance patterns can vary, and the use of meropenem-vaborbactam should be individualized based on local resistance patterns and patient-specific factors.",
                "The evidence for the advantage of aminoglycosides over tigecycline for complicated urinary tract infections (cUTI) is inconclusive. Some studies suggest that aminoglycosides may have similar efficacy to tigecycline, while others suggest that tigecycline may have a slightly better safety profile. Ultimately, the choice between these antibiotics depends on individual patient factors and clinician preference.",
                "Plazomicin and colistin are both antibiotics used to treat infections caused by Carbapenem-resistant Enterobacterales (CRE). While both drugs have activity against CRE, the evidence regarding their comparative efficacy is limited.\n\nPlazomicin has been shown to have similar or slightly better in vitro activity against CRE compared to colistin. However, there are limited head-to-head clinical trials directly comparing the two drugs. The available data suggest that plazomicin may have a slightly better safety profile than colistin, particularly in terms of nephrotoxicity.\n\nOverall, while there is some evidence to suggest that plazomicin may be as effective as colistin for the treatment of CRE infections, more studies are needed to confirm this. The choice between the two drugs should be based on individual patient factors,",
                "Yes, there are studies suggesting that colistin-carbapenem combination therapy may have a lower 28-day mortality rate compared to colistin monotherapy in patients with Carbapenem-resistant Enterobacteriaceae (CRE) infections. However, the evidence is not definitive and more research is needed to confirm this. It's important to note that individual patient outcomes can vary greatly depending on the specific infection, underlying health conditions, and other factors. Always consult with a healthcare professional for medical advice.",
                "Cefiderocol is a siderophore cephalosporin with activity against carbapenem-resistant Enterobacterales (CRE). The FDA approved cefiderocol for the treatment of complicated urinary tract infections and pyelonephritis caused by susceptible Gram-negative microorganisms, including CRE, based on the results of the SISPIRIT trial. This trial demonstrated non-inferiority of cefiderocol monotherapy compared to meropenem-doripenem combination therapy in the treatment of complicated urinary tract infections caused by CRE. However, it's important to note that the clinical context, patient characteristics, and local resistance patterns should be considered when deciding between monotherapy and combination therapy for CRE infections. Consulting the latest guidelines and seeking advice from an infectious disease specialist is recommended.",
                "The retrospective cohort study found that ceftolozane-tazobactam was associated with a higher clinical cure rate (83.3%) compared to polymyxins or aminoglycosides (63.6%). Ceftolozane-tazobactam also had a lower mortality rate (13.3%) compared to polymyxins or aminoglycosides (26.7%). However, it's important to note that retrospective studies have limitations and more well-designed studies are needed to confirm these findings.",
                "For severe infections caused by CRPA (Carbapenem-resistant Pseudomonas aeruginosa), the recommended antibiotic regimens include:\n\n1. Polymyxins (e.g., polymyxin B or E) in combination with an aminoglycoside (e.g., gentamicin or tobramycin).\n2. Monotherapy with a newer polymyxin (e.g., meropenem-vaborbactam or imipenem-relebactam) if susceptible.\n3. Fosfomycin in combination with an aminoglycoside or a beta-lactam antibiotic if susceptible.\n\nThese combinations aim to provide synergistic activity against CRPA and improve treatment outcomes. Always consult local guidelines and susceptibility data before making specific treatment decisions",
                "For patients with CRAB (Carbapenem-resistant Acinetobacter baumannii) and susceptible to sulbactam but resistant to other antibiotics in the setting of HAP (Healthcare-associated pneumonia) or VAP (Ventilator-associated pneumonia), the suggested treatment options may include:\n\n1. Polymyxins (e.g., colistin or polymyxin E)\n2. Amikacin or other aminoglycosides if the organism is not extensively resistant\n3. Tigecycline or other glycylcyclines\n4. Fosfomycin\n5. Ceaselessly monitoring for the emergence of resistance and adjusting therapy accordingly.\n\nIt's essential to note that the choice of antibiotic depends on the specific suscept",
                "Cefiderocol is an antibiotic with activity against gram-negative bacteria, including those commonly responsible for CRAB (community-acquired or healthcare-associated carbapenem-resistant acinetobacter baumannii) infections. Several studies have shown that cefiderocol is effective in treating CRAB infections, with success rates similar to or even superior to those of other antibiotics such as colistin and tigecycline. However, it's important to note that individual patient outcomes may vary, and the choice of antibiotic should be based on the specific infection and patient's individual circumstances. Always consult the latest clinical guidelines and literature for the most up-to-date information.",
                "Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB (Carbapenem-resistant Acinetobacter baumannii) infections. However, high-quality randomized controlled trials are needed to provide stronger evidence of its efficacy and safety. The combination therapy may improve outcomes by synergistic effects of both antibiotics against carbapenem-resistant A. baumannii.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections require specific antibiotic treatment due to their resistance to common antibiotics. Here are some general principles for antibiotic treatment:\n\n1. Identify the specific CR-GNB causing the infection through laboratory testing.\n2. Choose an antibiotic that is active against the identified CR-GNB.\n3. Consider the site of infection and the patient's overall health when selecting an antibiotic.\n4. Administer the antibiotic intravenously (IV) in severe infections or when the patient cannot take oral medication.\n5. Monitor the patient closely for adverse effects and drug interactions.\n6. Consider using combination therapy for infections caused by certain CR-GNB, such as P. aeruginosa or A. baumannii.\n7. Ensure adequate dosing",
                "For patients undergoing colorectal transplant surgery, preoperative screening typically includes colonoscopy to assess for colon cancer or precancerous lesions. For liver transplant patients, screening may include ultrasound, alpha-fetoprotein (AFP) level measurement, and hepatitis serology to assess for liver disease and liver cancer. These recommendations may vary based on individual patient risk factors and guidelines from professional organizations. Always consult with a healthcare provider for specific recommendations.",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Cephalosporin-Resistant Enterococci (ESCR-E) undergoing colorectal surgery is controversial. Some guidelines suggest considering alternative antibiotics for PAP, while others recommend using a different class of antibiotics altogether, such as aminoglycosides or glycopeptides. Ultimately, the decision should be individualized based on the specific patient's risk factors and the local antibiotic resistance patterns. Consulting with an infectious disease specialist or a colon and rectal surgeon is recommended for optimal management.",
                "The antibiotics that should be reserved for the treatment of extensively resistant bacteria (such as extensively drug-resistant Mycobacterium tuberculosis or carbapenem-resistant Enterobacteriaceae) include:\n\n1. Polymyxins (e.g., colistin)\n2. Tigecycline\n3. Amikacin (for certain types of bacteria)\n4. Bedaquiline (for M. tuberculosis)\n5. Delamanid (for M. tuberculosis)\n\nThese antibiotics should not be used routinely for targeted PAP (pre-exposure prophylaxis) in Extensively Drug-Resistant-Tuberculosis (ESCR-TB) carriers due to their potential toxicity, limited availability, and the development of resistance with overuse. Instead",
                "Recommended components for research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates include:\n\n1. Study design: Randomized controlled trials (RCTs) or observational studies.\n2. Study population: ESCR-E colonized SOT candidates.\n3. Intervention: Targeted PAP (pre-transplant antimicrobial prophylaxis) with specific antibiotics.\n4. Comparator: Standard of care or placebo.\n5. Outcomes: Primary outcome - post-transplant infections; secondary outcomes - graft function, adverse events, and microbiological outcomes.\n6. Sample size: Based on the expected effect size and power analysis.\n7. Study duration: From pre-transplantation to post-transplantation follow-up.",
                "Yes, a recommendation can be issued for targeted PAP using non-carbapenem antibiotics for patients colonized with CRE before surgery to reduce the risk of surgical site infections caused by CRE. However, the specific antibiotic choice should be based on local resistance patterns and patient factors. Consult local guidelines and infectious disease specialists for the most appropriate antibiotic selection.",
                "A good practice for screening Solid Organ Transplant (SOT) recipients for CRAB (Chronic Renal Allograft Abolition) before surgery is to assess their renal function with regular serum creatinine levels and estimated glomerular filtration rate (eGFR). Additionally, monitoring for proteinuria, hematuria, and signs of allograft dysfunction is essential. If there are concerns, a renal biopsy may be necessary to confirm CRAB. Regular follow-ups with a nephrologist are recommended for close monitoring.",
                "To investigate CRAB (Clostridioides difficile-associated diarrhea) colonization and targeted PAP (proteasome activating protein), the panel would suggest designing randomized controlled trials (RCTs) with a placebo or active comparator arm. These trials should include adequate sample size, proper study design, and standardized endpoints to assess the efficacy and safety of targeted PAP in preventing CRAB colonization. Additionally, consider using biomarkers to objectively measure CRAB colonization and response to treatment.",
                "In transplant surgery other than renal transplant, the suggested duration of post-operative positive airway pressure (PAP) varies depending on the specific type of transplant and individual patient's condition. Generally, it ranges from a few days to several weeks. For example, in liver transplant, PAP may be used for a few days to help prevent respiratory complications. In heart-lung transplant, PAP may be required for several weeks to help the lungs adjust to the new organ. It's important to consult with the transplant team for specific recommendations.",
                "The risk of Multidrug-resistant Gram-negative bacterial (MDR-GNB) infections in solid organ transplant (SOT) recipients is relatively high due to the use of immunosuppressive medications. These infections can lead to serious complications such as sepsis, organ failure, and increased mortality. Common MDR-GNB pathogens include P. aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Prevention strategies include strict infection control measures, appropriate antibiotic prophylaxis, and close monitoring for signs of infection.",
                "The suggested approach to identify FQR-E carriers before TRUSPB includes:\n\n1. Obtaining a urine culture before the procedure.\n2. Sensitivity testing for fluoroquinolones in the urine culture result.\n3. Considering alternative antibiotics for prophylaxis if FQR-E is identified.\n\nIt's important to note that the decision to test for FQR-E should be based on local prevalence and individual patient risk factors. Consult local guidelines and infectious disease specialists for specific recommendations.",
                "The specific outcome of the trial you're referring to is not readily available in a clear and short answer format, as I would need to access the study's results to provide an accurate response. However, in general, non-blinded trials may be subject to bias, and comparing ciprofloxacin PAP (prostate antimicrobial prostatease) to culture-based PAP (transrectal ultrasound-guided prostate biopsy with conventional culture) in fluoroquinolone-resistant carriers could affect the results due to potential differences in detection rates and antimicrobial efficacy. For the most accurate information, I would recommend looking up the specific study or consulting a urology or infectious disease specialist.",
                "Urinary colonization with MDR-GNB is a significant risk factor for postoperative infections in patients undergoing urologic surgery. These bacteria can cause infections during or after the procedure, leading to increased morbidity and mortality. Preoperative urine screening and appropriate antibiotic prophylaxis can help reduce the risk of these infections.",
                "A comprehensive approach to reducing surgical site infections (SSIs) includes:\n\n1. Preoperative preparation: Optimizing the patient's health, proper wound preparation, and prophylactic antibiotics.\n2. Intraoperative measures: Sterile environment, proper surgical technique, and use of sterile instruments.\n3. Postoperative care: Wound care, early ambulation, and appropriate use of drains and dressings.\n4. Infection control policies: Implementing standardized protocols, surveillance, and education for healthcare personnel.\n5. Patient selection and optimization: Addressing comorbidities and risk factors.\n6. Vaccination: Ensuring up-to-date vaccinations, especially for patients undergoing orthopedic surgery.\n7. Antimicrobial stewardship: Appropriate use of antibiotics to prevent and",
                "For standard operating procedures (SOPs) related to sampling site technique, it's important to follow these steps:\n\n1. Properly clean and prepare the sampling site.\n2. Use sterile equipment for sampling.\n3. Collect sufficient sample size.\n4. Transport samples to the lab in appropriate containers and at proper temperature.\n\nFor microbiological methods, SOPs should include:\n\n1. Properly handling and transporting samples.\n2. Using appropriate media for culturing.\n3. Incubating samples at the correct temperature and time.\n4. Identifying and reporting results according to established protocols.",
                "When choosing targeted PAP for CRE infections, consider the following factors:\n\n1. Type and site of surgery: The risk of surgical site infection (SSI) varies depending on the type and site of surgery.\n2. Patient risk factors: Factors such as age, comorbidities, and underlying conditions increase the risk of SSI.\n3. Type and susceptibility of CRE: The specific type and susceptibility of the CRE strain can influence the choice of antibiotic.\n4. Allergies and drug interactions: Patients may have allergies or drug interactions that limit the choice of antibiotics.\n5. Duration of antibiotic therapy: The length of antibiotic therapy should be based on the type and site of surgery and the susceptibility of the CRE strain.\n6. Cost and availability: The cost and availability of antibiotics should",
                "Colonization of a patient with bacteria or other pathogens that can cause infections is important to know before solid organ transplantation (SOT) because:\n\n1. Transplant recipients are at increased risk for infections due to immunosuppressive therapy.\n2. Certain bacteria or viruses can cause severe infections in the transplanted organ or other parts of the body.\n3. Antibiotic prophylaxis or other preventive measures can be taken to reduce the risk of infection in the peri-transplant period.\n4. Some infections may require delaying or even canceling the transplant procedure.\n5. Knowing the colonization status can help guide the choice of antibiotic prophylaxis and other preventive measures."
            ],
            "no additional prompt / context": [
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including Bloodstream Infections (BSI), Urinary Tract Infections (UTI), pneumonia, and intra-abdominal infections (IAI). The studies referred to in the text are described in Table 3. The data available on 3GCephRE are mainly derived from observational studies in the hospital setting, and there is a lack of information on the bacterial species and mechanisms of resistance in many studies. The evidence on new antibiotics is sparse due to the small subgroups of patients with 3GCephRE infections in most new antibiotic approval RCT. The studies address the choice of antibiotic treatment in the context of PICO 1. For specific antibiotics like quinolones, aminoglycosides, cefoperazone",
                "The retrospective observational studies comparing carbapenems with non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, for the treatment of 3GCephRE infections did not find statistically significant differences between the groups. However, the sample sizes were very small in all studies, ranging from 10 to 23 patients in the cephalosporin group. Therefore, the evidence from these studies supports moderate-certainty for the use of non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, as carbapenem-sparing alternatives for the treatment of 3GCephRE infections.",
                "The five retrospective observational cohort studies evaluated mortality in patients with 3GCephRE BSI who received either cephamycins (cefmetazole or flomoxef) or carbapenems. The overall certainty of the evidence was very low due to the retrospective nature of the studies and the small sample sizes. However, all studies suggested higher mortality with cephamycins compared to carbapenems. One study also showed higher mortality with flomoxef compared to imipenem [56]. The evidence for a possible advantage of carbapenems over cephamycins was very low. Cefepime, another cephamycin, may be active against AmpC-producing 3GcephRE, but the evidence for its use in 3GCephRE BSI is limited. Therefore, based on",
                "None of the studies found statistically significant differences between cephamycins and cefepime, and carbapenems for the treatment of pyelonephritis caused by 3GCephRE. The overall certainty of the evidence was low due to the high risk of bias in all studies. Therefore, the evidence does not provide strong support for the use of cephamycins or cefepime over carbapenems for this indication.",
                "The retrospective observational studies compared carbapenems with various non-carbapenem antibiotics, primarily BLBI, quinolones, and aminoglycosides, for the treatment of complicated urinary tract infections (UTI), including those with or without bacteriaemia. Nine such studies were identified, with two addressing empirical treatments and all but one analyzing the targeted treatment phase. The findings suggested that there is moderate-certainty evidence for the use of aminoglycosides as a carbapenem-sparing alternative for the treatment of cUTI, given the moderate risk of bias and the absence of significant differences in mortality or relapse between aminoglycosides and carbapenems or piperacillin-tazobactam in one adjusted analysis. However, due to the paucity of data and observational design",
                "Based on the context provided, there is a lack of RCTs specifically evaluating various antibiotics for the treatment of IAI caused by 3GCephRE. The evidence is mainly derived from observational studies in the hospital setting. However, some studies have reported favorable effects of targeted quinolone therapy for Gram-negative bacteriaemia, where a proportion of patients is expected to have had 3GCephRE IAI. Aminoglycosides were examined in a single study and as part of a general comparator group in two studies. The evidence on the use of new antibiotics for 3GCephRE IAI is limited due to the small subgroups of patients with 3GCephRE infections in most new antibiotic approval RCTs.",
                "Based on the information provided in the context, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE based on the results of the Tango-II RCT. However, it is important to note that the evidence is moderate due to the limitations of the study, including the small sample size and the focus on K. pneumoniae infections. Additionally, the comparison was with various monotherapies and combinations, so the direct comparison to best available treatment may have some limitations.",
                "Based on the information provided in the context, there is moderate-level evidence for the advantage of aminoglycosides over tigecycline for the treatment of complicated urinary tract infections (cUTI). This evidence includes two prospective studies from the CRaCKle cohort suggesting better clinical outcomes with aminoglycoside-containing regimens compared with tigecycline-containing regimens [124,125]. Additionally, a retrospective cohort study found no significant advantage in mortality or relapse for carbapenem or piperacillin-tazobactam over aminoglycosides for the treatment of cUTI [69]. However, the risk for nephrotoxicity increases after 7 days of aminoglycoside therapy [75], so shorter durations are recommended",
                "Based on the context provided, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The CARE-RCT study, which was designed to compare the two treatments, was suspended after 2 years due to enrolment difficulties, and the available results do not provide sufficient data for comparison.",
                "Based on the information provided in the context, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. The results from the AIDA and OVERCOME trials did not show any statistically significant differences in 28-day mortality between the two groups. However, it is important to note that there is still insufficient evidence to make a definitive conclusion about the comparative efficacy of colistin versus other antibiotics for CRE, including carbapenems.",
                "Based on the evidence presented in the context, there is conflicting data regarding the use of antibiotic combination versus monotherapy in patients with CRE infections and the results are not definitive [97,123,128,130,139,140,143-171]. In the CREDIBLE RCT, clinical and microbiological cure rates were similar for patients receiving cefleforocol monotherapy versus ceftoferocol combination therapy, but there were no separate results presented for CRE and mortality data were not available [121].\n\nRegarding cefiderocol specifically, in patients with baseline monomicrobial CRE infections, mortality at the end of the study was similar for those receiving cefiderocol monotherapy versus BAT (Beta-lactam/Beta-lact",
                "The retrospective cohort study compared the outcomes of 100 patients with MDR/XDR P. aeruginosa mixed infections who received ceftolozane-tazobactam, and 100 patients who received polymyxins or aminoglycosides [194]. The study did not provide information on the number of patients with CRPA specifically. The study found no significant difference in mortality, microbiological eradication, or development of resistance between the two groups. However, clinical care was higher and nephrotoxicity was lower in the ceftolozane-tazobactam group, although the study had a high risk of bias due to the unclear patient selection, lack of adjustment for baseline differences, and limited data on carbapenem resistance.",
                "Based on the context provided, the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use a combination therapy of two in vitro active drugs (conditional recommendation for use, very low certainty of evidence).",
                "Based on the context provided, the suggested treatment for patients with CRAB (Carbapenem-resistant Acinetobacter baumannii) and susceptible to sulbactam for HAP/VAP (Hospital-acquired pneumonia/Ventilator-associated pneumonia) is ampicillin-sublactam (conditional recommendation, low certainty of evidence).",
                "Based on the available evidence from clinical trials, such as the CREDIBLE and APEKS-NP RCTs, there is low-certainty evidence against the use of cefiderocol for the treatment of CRAB infections. Specifically, in the CREDIBLE trial, among patients with CRAB infections, the 28-day mortality rates were higher in the cefiderocol group compared to the BAT group. In the APEKS-NP RCT, similar mortality, clinical, and microbiological outcomes were observed for cefiderocol and high-dose extended-infusion meropenem in a subgroup of patients with pneumonia and A. baumannini species with meropenem MIC >8 mg/mL.\n\nHowever, it is important to note that the evidence is limited, and there is a lack of direct",
                "Observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections have shown conflicting results. Some studies reported a significant association between the use of this combination therapy and survival or clinical cure [198, 235, 247]. However, other studies did not show such an association [199, 244]. It is important to note that many of these observational studies included patients treated with a polymyxin-carbapenem combination in a larger group of patients treated with different combination therapies. From these studies, it is difficult to assess the specific effects of a polymyxin-carbapenem combination regimen. Overall, the evidence from observational studies is limited and of very low certainty due to the risk of bias and confounding factors.",
                "1. There is no high-certainty evidence pointing to a preferred antibiotic treatment for CR-GNB infections.\n2. For new antibiotics like imipenem-relebactam, only limited data are available. For instance, imipenem-relebactam has been tested against CR-GNB in the RESTORE-IMI 1 trial.\n3. Some antibiotics, such as tigecycline, have shown an increased risk of death for HAP, VAP, and bacteremia, but not specifically for CR-GNB.\n4. Cefiderocol, a novel siderophore cephalosporin, has conflicting results in treating CR-GNB. While it is non-inferior to carbapenems for UTI and HAP/VAP caused by carbapenem",
                "Based on the context provided, the suggested screening approach for patients undergoing colorectal and liver transplant surgery is as follows:\n\n        1. For Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E):\n           a. We suggest rectal screening to identify ESCR-E carriers before colorectal and liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence).\n           b. It might be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epidemiology (ungraded good practice statement).\n\n        2. For Carbapenem-resistant Acinetobacter baumannii (CRAB):\n           a. We conditionally recommend implementing rectal screening to identify CRAB carriers before liver transplant",
                "Based on the available evidence, we conditionally recommend targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery (conditional recommendation for use, low certainty of evidence). It might also be a good practice to consider targeted PAP for all SOT recipients who are colonized with ESCR-E before surgery (ungraded good practice statement). The use of etapenem-based PAP has shown potential benefits in reducing SSIs in ESCR-E carriers undergoing colorectal surgery, as shown in a multicenter study and a retrospective study. However, more high-quality evidence is needed to confirm these findings.",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. The use of carbapenems should also be limited if other antibiotic options are available against ESCR-E, considering antimicrobial stewardship.",
                "The panel recommends that research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates should include the postsurgical monitoring of antibiotic resistance. This recommendation is based on the very low evidence for targeted PAP effectiveness in ESCR-E carriers undergoing liver transplantation and the lack of evidence for other transplant surgeries. Further studies are needed to assess the impact of targeted PAP in this population.",
                "Based on the current evidence, no definitive recommendation can be issued for or against targeted PAP for patients who are colonized with CRE before surgery. The limited evidence available suggests that the impact of targeted PAP on infectious complications following urologic surgery in CRE carriers is not well established. While rectal colonization may not be informative, urinary cultures are often obtained for treating asymptomatic bacteriuria before surgery, as recommended by clinical practice guidelines. However, it is important to note that the knowledge of CRE colonization in high-risk patients, such as those undergoing transplant surgery, is relevant for infection control purposes and for the adaptation of postsurgical empirical treatment in case of severe infections. Therefore, further research is needed to assess the impact of CRE rectal screening in high-risk surgeries and to investigate the mechanisms of resistance of newly isolated MDR",
                "According to the context provided, it is recommended as a good practice to screen all SOT recipients for CRAB (Carbapenem-resistant Acinetobacter baumannii) before surgery, based on the local epidemiology. The decision to implement screening should be based on the prevalence of CRAB colonization or infection among patients admitted or transferred to the surgical wards. A prevalence of >=10% is suggested as a cut-off for implementation evaluation. Future research is recommended to assess the impact of XDRPA (Extended-spectrum Deltaproteobacteria and Pseudomonas aeruginosa) screening on post-SOT infections and to compare the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery. The timing for preoperative MDR-GNB (Multid",
                "The panel suggests designing clinical trials to investigate the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in clinical trials.",
                "Based on the context provided, there is currently no formal consensus on the duration of PAP in transplant surgery other than renal transplant. Recommendations based on expert opinion suggest the administration of PAP for less than 24 hours in kidney transplant, 24-48 hours in liver, heart, pancreas transplant, and for 48-72 hours in intestinal/multivisceral and lung transplantation. However, in some cases, such as lung recipients with respiratory colonization or infection and intestinal or multivisceral transplant with infected mesh or fistulas, prolonged PAP treatment may be required.\n\nIt is important to note that the optimal duration of PAP in MDR-GNB carriers should follow the same principles as in non-carriers to minimize the risks associated with prolonged antibi",
                "The risk of MDR-GNB infections in solid organ transplant (SOT) recipients is significant due to their prolonged hospitalization, invasive procedures, ICU admission, and broad-spectrum antibiotic treatment [63,64]. The rates of CRAB and MDR PA in bloodstream infections (BSIs) among nonfermenters have been reported up to 63% and 52%, respectively [66,68,69]. Post-SOT infections caused by MDR-GNB are associated with higher mortality compared with their susceptible counterpart [26,62,65,70,71,72,73].\n\nAmong SOT recipients, post-transplant CRE infections were documented in 40% of cases, and 35% of SOT recipients received targeted",
                "Based on the context provided, the European Association of Urology (EAU) suggests rectal screening to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence). This recommendation is due to the increased rates of FQR-E colonization reported before TRUSPB and the potential for increased infectious complications in FQR-E carriers. The use of targeted PAP for patients who are colonized with FQR-E before TRUSPB is also suggested as a conditional recommendation with moderate certainty of evidence.",
                "The randomized, non-blinded, multicenter trial compared ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, including 1288 patients, 15.8% of whom were FQR carriers. The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for the culture-based PAP group compared to the ciprofloxacin PAP group. However, the results should be interpreted with caution due to the non-blinded design of the study. Further high-quality, blinded trials are needed to confirm these findings, particularly in the context of FQR carriers.",
                "Based on the context provided, there is limited evidence on the impact of targeted preoperative antibiotic prophylaxis (PAP) on infectious complications following urologic surgery in patients colonized with MDR-GNB. Urinary cultures are often obtained before surgery to identify and treat asymptomatic bacteriuria, but the role of targeted PAP based on preoperative cultures in reducing postoperative infections in MDR-GNB carriers is not well established. Higher rates of postoperative infections have been reported in patients with urinary colonization compared to noncolonized patients, and patients undergoing urologic surgery often have risk factors for MDR-GNB acquisition. However, studies comparing postoperative infections in MDR-GNB urinary carriers versus noncarriers are lacking. Therefore, further research is needed to identify the impact of MDR-GN",
                "The comprehensive approach required to reduce surgical site infections (SSIs) involves a combination of antibiotic-based interventions and best surgical practices. Some of these practices include minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, and managing patient comorbidities. Recent trials in colorectal surgery have shown that the use of oral antibiotics, with or without mechanical bowel preparation, may reduce the risk of SSIs. However, there is a need for protocols exploring the use of oral therapy with activity on Multi-Drug Resistant Gram-Negative Bacteria (MDR-GNB). While coordinated actions such as decolonization, active surveillance, and stewardship measures have contributed to SSIs reduction for MDR Gram-positive bacteria, no bundles complementing PAP in MDR-GNB carriers under",
                "Based on the context provided, it is recommended that any changes to sampling site technique and microbiological methods for detecting Carbapenem-resistant Acinetobacter baumannii (CRE) or Extended-spectrum CRE (ESCR-E) infections in surgical wards should follow a careful assessment of the local prevalence of CRE colonization and infection. The choice of targeted versus universal screening should be based on the local work organization and integrated within diagnostic and antibiotic stewardship guidance. It is also important to consider local epidemiology, microbiological capacity, available financial resources, and patient risk factors for CRE acquisition when making changes to screening and PAP policies.\n\nRegarding sampling site technique, the context suggests that screening of different body sites, such as skin, should be considered as part of evidence-based screening protocols. However, specific details on sampling site",
                "1. Screening for CRE before surgery: While there is no strong evidence to recommend rectal screening for all patients before surgery to identify CRE carriers, it may be considered in high-risk patients undergoing transplant surgery based on local epidemiology (conditional recommendation, low certainty of evidence).\n        2. Antimicrobial stewardship: Knowledge of CRE colonization in high-risk patients is important for infection control purposes and for the adaptation of postsurgical empirical treatment.\n        3. Clinical trials: Designing clinical trials to assess the impact of CRE rectal screening in high-risk surgeries and evaluating the effectiveness of targeted PAP in specific surgical groups, such as ESCR-E carriers undergoing high-risk procedures, is recommended.\n        4. Postsurgical monitoring: Postsurgical monitoring of",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) for several reasons. First, if a patient is colonized with multidrug-resistant microorganisms (MDR-GNB), this information can help inform infection control measures to reduce the risk of intra-hospital and community spreading. Second, the knowledge of CRAB (Carbapenem-resistant Acinetobacter baumannii) colonization in high-risk patients such as those receiving transplant surgery is relevant for the adaptation of postsurgical empirical treatment, particularly in case of severe infections. Lastly, the choice of targeted versus universal screening should be based on local work organization and integrated within antibiotic and diagnostic stewardship guidance. Overall, the early implementation of infection control procedures based on the patient's colonization status before SOT is essential for optimizing"
            ],
            "additional prompt / context": [
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome: Bloodstream Infections (BSI), Urinary Tract Infections (UTI), pneumonia, and intra-abdominal infections (IAI). The studies referred to in the text are described in Table 3. However, it's important to note that the evidence is mainly derived from observational studies, and there is a lack of data on targeted quinolone therapy for 3GcephRE BSI. For other antibiotics like aminoglycosides, cefoperazone-sulbactam, ampicillin-sulbactam, ticarcillin-clavulanic acid, temocillin, and mecillinam, there is insufficient evidence for their management in 3GCephRE infections.",
                "None of the nine retrospective observational studies found statistically significant differences between carbapenems and any other non-carbapenem antibiotic, including BLBLI, quinolones, and aminoglycosides, in the treatment of 3GCephRE infections.",
                "The five retrospective observational studies evaluated mortality in patients with 3GCephRE BSI treated with cephamycins (cefmetazole or flomoxef) versus carbapenems. The overall certainty of the evidence was very low due to the observational nature of the studies and the lack of randomization or blinding. The results showed conflicting outcomes, with some studies suggesting similar or better outcomes with cephamycins and others suggesting worse outcomes compared to carbapenems. However, the sample sizes were small and appropriate adjustments were not possible in most studies due to the retrospective design. Therefore, the evidence does not support a definitive recommendation for or against the use of cephamycins versus carbapenems for the treatment of 3GCephRE BSI.",
                "None of the studies found statistically significant differences between cephamycins and cefepime, and carbapenems for the treatment of pyelonephritis caused by 3GCephRE. The overall certainty of the evidence was low due to the high risk of bias in all studies.",
                "Based on the context provided, nine retrospective observational studies compared carbapenems with other non-carbapenem antibiotics for the treatment of complicated UTI. The studies analyzed the targeted treatment phase and included mainly BLBI, quinolones, and aminoglycosides as carbapenem-sparing regimens. However, the evidence is of moderate certainty due to the observational design and potential biases. No significant difference in mortality or clinical cure was found between carbapenems and non-carbapenem antibiotics. Therefore, the use of non-carbapenem antibiotics as carbapenem-sparing regimens for the treatment of complicated UTI is supported by moderate-level evidence.",
                "Based on the context provided, there is a lack of RCTs specifically evaluating various antibiotics for the treatment of IAI caused by 3GCephRE. The evidence is mainly derived from observational studies. Therefore, no definitive finding can be made from the RCTs mentioned in the text regarding the treatment of IAI caused by 3GCephRE with specific antibiotics.",
                "Based on the Tango-II RCT, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE.",
                "The level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is moderate, based on two prospective studies suggesting better clinical outcomes with aminoglycoside-containing regimens and one retrospective study showing no significant difference in mortality or relapse for carbapenem or piperacillin-tazobactam over aminoglycosides. However, there is insufficient evidence for other comparisons and sources of infection. Additionally, the risk for nephrotoxicity increases after 7 days of aminoglycoside therapy, so shorter durations are recommended. There is also evidence of a higher rate of hospital readmission at 90 days and lower microbiological cure with tigecycline-based combinations compared with aminoglycoside-containing combinations for cUTI.",
                "No, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The CARE-RCT study, which was designed to test the difference between the two, was suspended due to enrolment difficulties, leaving limited data available.",
                "Based on the available evidence from the AIDA and OVERCOME trials, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. (p > 0.05)",
                "Based on the evidence reviewed, there is conflicting data on the use of combination therapy versus monotherapy with cefiderocol in the treatment of CRE infections. The CREDIBLE RCT did not show significant differences in clinical and microbiological cure rates or mortality between cefiderocol monotherapy and BAT (combination therapy) in patients with CRPA infections. However, the number of patients was very small and the evidence is of very low certainty for non-inferiority of cefiderocol monotherapy compared with BAT. Therefore, the use of cefiderocol monotherapy versus combination therapy in the treatment of CRE infections remains uncertain and should be considered on an individual basis.",
                "The retrospective cohort study reported no significant difference in mortality between patients treated with ceftolozane-tazobactam and those given polymyxins or aminoglycosides [194]. However, clinical care was better and nephrotoxicity was lower in the ceftolozane-tazobactam group. The study had a high risk of bias due to the lack of adjustment for patient selection and baseline differences between groups.",
                "Based on the context provided, the recommendation is to treat severe infections caused by CRPA with two in vitro active drugs when using polymyxins, aminoglycosides, or fosfomycin (conditional recommendation for use, very low certainty of evidence).",
                "The suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP is ampicillin-sulbactam.",
                "Based on the available evidence from clinical trials, cefiderocol does not show a clear advantage over other antibiotics, such as BAT or meropenem, in terms of clinical or microbiological efficacy for CRAB infections. In fact, there is evidence suggesting higher mortality rates with cefiderocol compared to BAT in patients with CRAB infections in the CREDIBLE trial. Therefore, we conditionally recommend against the use of cefiderocol for the treatment of CRAB infections, based on low certainty of evidence. Other antibiotics with proven efficacy against CRAB, such as eravacycline, should be considered instead.",
                "Observational studies on polymyxin-carbapenem combination therapy for CRAB infections have shown conflicting results. Some studies reported a significant association between the use of this combination and survival or clinical cure, while others did not. However, it is important to note that many of these studies included patients treated with a polymyxin-carbapenem combination in a larger group of patients treated with different combination therapies. The effects of a specific polymyxin-carbapenem combination regimen cannot be definitively assessed from these studies.",
                "1. There is no high-certainty evidence for a preferred antibiotic for CR-GNB infections.\n2. Imipenem-relebactam is the only new BLBLI with proven efficacy against CR-GNB in a randomized controlled trial.\n3. Cefiderocol, a novel siderophore cephalosporin, has conflicting results in clinical trials for CR-GNB.\n4. Tigecycline is associated with an increased risk of death and low-certainty evidence supports sublactam-based therapy over it.\n5. Follow-up cultures are recommended for treatment failure, especially for CR-GNB.\n6. The least resistant antibiotic/s based on MICs and optimal source control should be considered for pan-resistant CR-GNB.\n7. Antibiotic",
                "The suggested approach is to perform rectal screening for Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before both colorectal and liver transplant surgery, according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery (ungraded good practice statement).",
                "We conditionally recommend targeted PAP using agents such as etapenem in patients colonized with ESCR-E undergoing colorectal surgery (conditional recommendation for use, low-moderate certainty of evidence).",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers.",
                "1. The impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates should be investigated in further studies.\n2. Research protocols should include the postsurgical monitoring of antibiotic resistance, such as XDRPA screening, to assess the risk of post-SOT infections among carriers.",
                "Based on the current evidence, no definitive recommendation can be made for or against targeted PAP for patients colonized with CRE before surgery. Further research is needed to assess the impact of CRE rectal screening in high-risk surgeries and the development of resistance to antibiotics used for targeted regimens.",
                "It is a good practice to screen SOT recipients for CRAB (Carbapenem-resistant Acinetobacter baumannii) before surgery, according to the local epidemiology (ungraded good practice statement). The decision to implement screening should be based on the prevalence of CRAB colonization or infection among patients admitted or transferred to the surgical wards. A prevalence of >=10% is suggested as a cut-off for implementation evaluation (conditional recommendation, low certainty of evidence). Future research is recommended to assess the impact of XDRPA (extended-spectrum cephalosporin and fluoroquinolone resistance in Acinetobacter baumannii) screening on post-SOT infections and the efficacy of targeted versus routine PAP (polymerase chain reaction) in CRAB carriers (conditional use in restricted trials).",
                "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in clinical trials.",
                "Based on current recommendations and expert opinion, the suggested duration of PAP in transplant surgery other than renal transplant is 48-72 hours. However, this is subject to the specific type of transplant and individual patient circumstances. For some procedures, prolonged PAP treatment may be necessary.",
                "The risk of MDR-GNB infections in SOT recipients is significant, with reported rates of CRAB and MDR PA up to 63% and 52%, respectively, in bloodstream infections. Post-SOT infections caused by MDR-GNB are associated with higher mortality compared with their susceptible counterpart. Early detection of MDR-GNB carriers through active surveillance can inform contact precautions and may be useful in guiding treatment for postoperative infections. However, the benefits of active surveillance in asymptomatic SOT patients, non-outbreak settings, or regions of endemicity are questioned. SOT recipients are at increased risk for MDR-GNB infections due to prolonged hospitalization, invasive procedures, ICU admission, and broad-spectrum antibiotic treatment. Common issues include SSIs and LTR infections,",
                "We suggest rectal screening to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
                "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for patients receiving culture-based PAP compared to ciprofloxacin PAP. However, this difference was not statistically significant. The impact of this result on FQR carriers specifically is not explicitly stated in the provided information.",
                "There is limited evidence on the impact of targeted preoperative antibiotic prophylaxis (PAP) based on urinary cultures for patients colonized with MDR-GNB on postoperative infections following urologic surgery. Higher rates of postoperative infections have been reported in MDR-GNB urinary carriers compared to noncarriers, but studies comparing infections in these groups are lacking. Further research is needed to identify the effect of MDR-GNB colonization and targeted PAP on postoperative infections and to optimize targeted PAP for different MDR-GNB based on the type of urological procedure and local antibiotic resistance patterns.",
                "A comprehensive approach to reduce SSIs involves the use of antibiotic-based interventions, such as targeted preoperative antibiotic prophylaxis (PAP) for MDR-GNB carriers, and best surgical practices. These practices include minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, and managing patient comorbidities. Recent trials in colorectal surgery suggest that the use of oral antibiotics may also reduce the risk of SSIs. However, there is a need for more studies investigating the effect of antibiotic treatment on the microbiota composition and patients' colonization dynamics over time within new protocols or bundled interventions targeting MDR-GNB.",
                "1. Sampling site technique: The sampling site should be chosen based on local epidemiology and infection patterns. Proper aseptic technique should be used during sampling to minimize contamination.\n        2. Microbiological methods: Sensitivity and specificity of microbiological methods should be considered. Standardized methods, such as culture-based or molecular methods, should be used to ensure accurate detection of CRE.\n        3. Timing of sampling: Sampling should be done at appropriate intervals to capture colonization or infection status accurately.\n        4. Reporting and follow-up: Rapid and reliable reporting of results is essential for timely implementation of infection control measures. Follow-up testing may be necessary to monitor the effectiveness of interventions.\n        5. Integration with antibiotic and diagnostic stewardship: Screening results should be integrated with antibiotic and diagnostic stewardship programs to",
                "1. Screening for CRE before surgery: Depending on local epidemiology, rectal screening for CRE carriers before high-risk surgeries, such as liver transplant, is recommended (conditional recommendation, low certainty of evidence).\n        2. Antimicrobial stewardship: Knowledge of CRE colonization in high-risk patients is essential for adapting postsurgical empirical treatment, especially in case of severe infections.\n        3. Clinical trials: Designing clinical trials to assess the impact of CRE rectal screening in high-risk surgeries and evaluating the effectiveness of targeted PAP in specific surgical groups, such as ESCR-E carriers undergoing high-risk procedures.\n        4. Postsurgical monitoring: Monitoring for antibiotic resistance, including CRE colonization through rectal cultures",
                "1. Knowing a patient's colonization status before SOT is essential for early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading.\n2. This information is particularly relevant for high-risk patients, like those undergoing transplant surgery, as it can inform the adaptation of postsurgical empirical treatment in case of severe infections.\n3. The choice between targeted and universal screening should be based on local work organization and integrated within antibiotic and diagnostic stewardship guidance.\n4. The evidence suggests that CRAB (Carbapenem-resistant Acinetobacter baumannii) colonization increases the risk of infections in patients undergoing SOT.\n5. However, more research is needed to determine the optimal timing for preoperative screening and the benefits of additional screening in case of recent antibiotic treatment."
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.05825995970071625,
                    "2_gram": 0.1086544286689707,
                    "3_gram": 0.08245166342278999,
                    "4_gram": 0.05762861075592003
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.15950488055112882,
                        "recall": 0.49337001319598367,
                        "fmeasure": 0.2321360593614503
                    },
                    "rouge_L": {
                        "precision": 0.10627614184215597,
                        "recall": 0.3464475984983581,
                        "fmeasure": 0.15717844070388162
                    }
                },
                "METEOR": 0.23319947465371624,
                "BERTScore": {
                    "Precision": -0.05,
                    "Recall": 0.188,
                    "F1_measure": 0.066
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.07727498139803828,
                    "2_gram": 0.14304701539742642,
                    "3_gram": 0.11089397247759285,
                    "4_gram": 0.07784888694697885
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20930895927064935,
                        "recall": 0.48220175693478623,
                        "fmeasure": 0.2773765627831704
                    },
                    "rouge_L": {
                        "precision": 0.14217141211985482,
                        "recall": 0.3310637194145358,
                        "fmeasure": 0.18884870776000837
                    }
                },
                "METEOR": 0.2528374413158506,
                "BERTScore": {
                    "Precision": 0.031,
                    "Recall": 0.229,
                    "F1_measure": 0.129
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.07639244590000416,
                    "2_gram": 0.15420027012181955,
                    "3_gram": 0.15035008672493994,
                    "4_gram": 0.12193738637846847
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.28534730580999573,
                        "recall": 0.7459162466912541,
                        "fmeasure": 0.3929346284534456
                    },
                    "rouge_L": {
                        "precision": 0.21256592028895133,
                        "recall": 0.5644368021634004,
                        "fmeasure": 0.29395433163682794
                    }
                },
                "METEOR": 0.4586352693815861,
                "BERTScore": {
                    "Precision": 0.145,
                    "Recall": 0.469,
                    "F1_measure": 0.301
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.12692074715300072,
                    "2_gram": 0.23152575149255947,
                    "3_gram": 0.22500099299863507,
                    "4_gram": 0.1851400943404325
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.41789551121309715,
                        "recall": 0.6872176457545525,
                        "fmeasure": 0.48302964033525747
                    },
                    "rouge_L": {
                        "precision": 0.3418257468936416,
                        "recall": 0.5559869670459585,
                        "fmeasure": 0.39400860555468226
                    }
                },
                "METEOR": 0.4675384527001352,
                "BERTScore": {
                    "Precision": 0.308,
                    "Recall": 0.502,
                    "F1_measure": 0.401
                }
            }
        }
    },
    {
        "parameters": {
            "embedding model": "BAAI/bge-small-en-v1.5",
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 256,
            "overlap": 25,
            "top_k": 5,
            "max new tokens": 190,
            "re-ranking": 0,
            "top_n": 0
        },
        "queries": [
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the retrospective observational studies comparing carbapenems with non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, for the treatment of 3GCephRE infections?",
            "What was the finding of the studies evaluating cephamycins (cefmetazole or flomoxef) versus carbapenems for the treatment of 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated UTI?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "None of the studies found a significant difference in outcomes between carbapenems and non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, although some studies reported a trend in favour of carbapenems or non-carbapenem-sparing antibiotics, but the evidence was limited by small sample sizes and residual differences between groups despite adjustment.",
            "The studies found no significant difference in mortality between cephamycins and carbapenems, except for one study that found an association between flomoxef therapy and mortality when the MIC was elevated within the susceptible range, but the overall certainty of the evidence was very low due to limitations in study design and sample size.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found no significant differences in clinical cure and microbiological outcomes between carbapenems and non-carbapenem antibiotics, including BLBLI, which achieved similar outcomes to carbapenems, with moderate-certainty evidence.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study design, such as randomized controlled trials (RCTs), observational studies, or systematic reviews. RCTs are considered the gold standard for evaluating the efficacy and safety of new treatments, while observational studies can provide valuable real-world data on how a treatment is used in clinical practice.\n2. Clinical guidelines: Clinical guidelines provide evidence-based recommendations for the diagnosis, prevention, and treatment",
                "Retrospective observational studies have compared the use of carbapenems with non-carbapenem antibiotics, including cephalosporins, quinolones, and aminoglycosides, for the treatment of infections caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). The findings of these studies have suggested that carbapenems are generally more effective in achieving microbiological and clinical cure compared to non-carbapenem antibiotics.\n\nHowever, it is important to note that these studies have several limitations, including selection bias, lack of standardized definitions for infection and outcome, and potential confounding factors. Additionally, the emergence of carbapenem-resistant bacteria, such as carbapenem-resistant Enterobacterales (CRE), has challenged the use of carb",
                "Several studies have compared the effectiveness and safety of cephamycins (cefmetazole or flomoxef) and carbapenems for the treatment of 3rd generation cephalosporin-resistant bloodstream infections (3GCephRE BSIs). Here are some key findings from these studies:\n\n1. Efficacy: The studies suggest that both cephamycins and carbapenems have similar efficacy in the treatment of 3GCephRE BSIs. However, some studies have shown that carbapenems may have a slightly higher success rate in achieving microbiological and clinical cure.\n2. Safety: Cephamycins are generally considered to be less toxic than carbapenems. However, they may cause more frequent and severe diarrhea compared to carbapenems.\n3. Resistance: The emergence of resistance",
                "Several studies have compared the effectiveness and safety of cephamycins (cefotetan and ceftriaxone) and cefepime to carbapenems (imipenem and meropenem) in the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase producing Enterobacteriaceae (3GCephre).\n\nA systematic review and meta-analysis of 12 randomized controlled trials (RCTs) by Zhang et al. (2018) found that cephamycins and cefepime were non-inferior to carbapenems in terms of clinical cure rate, microbiological eradication rate, and adverse events. However, subgroup analysis suggested that cefepime might be superior to carbapenems in achieving microbiological eradication in patients with severe",
                "Retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated urinary tract infections (UTIs) have yielded conflicting results. Some studies suggest that carbapenems may be more effective in achieving microbiological and clinical cure, particularly in cases of multidrug-resistant pathogens or complicated UTIs caused by Gram-negative bacteria. However, other studies have not shown significant differences in outcomes between carbapenems and non-carbapenem antibiotics.\n\nOne meta-analysis of 12 retrospective studies found that carbapenems were associated with a higher microbiological cure rate (OR 1.35, 95% CI 1.05-1.73) and a lower risk of treatment failure (OR 0.58, 95% C",
                "Several randomized controlled trials (RCTs) have evaluated the effectiveness of various antibiotics for the treatment of intra-abdominal infections (IAIs) caused by third-generation cephalosporin-resistant Enterobacterales (3GCRE). Here are some key findings from these studies:\n\n1. Carbapenems: Carbapenems, such as imipenem, meropenem, and ertapenem, have shown superiority over older antibiotics like ampicillin-sulbactam and cefotaxime in the treatment of 3GCRE-caused IAIs. Carbapenems have a broader spectrum of activity against Gram-negative bacteria, including 3GCRE, and are associated with higher clinical cure rates and lower mortality rates.\n2. Fluoroquinolones",
                "Meropenem-vaborbactam (MVB) is a carbapenem-beta-lactamase inhibitor combination antibiotic that has shown activity against certain carbapenem-resistant Enterobacterales (CRE), including those producing NDM-1 and OXA-48-type carbapenemases. The advantage of MVB over best available treatment for susceptible CRE is supported by several studies with varying levels of evidence.\n\n1. Randomized Controlled Trials (RCTs): A few small RCTs have compared MVB to other antibiotics for the treatment of infections caused by susceptible CRE. For example, a multicenter, randomized, non-inferiority trial (NCT02929593) compared MVB to imipenem-relebactam",
                "The comparative effectiveness and safety of aminoglycosides versus tigecycline for the treatment of complex urinary tract infections (cUTI) have been studied in several clinical trials. However, the evidence is not clear-cut, and the results are inconsistent.\n\nA systematic review and meta-analysis of 13 randomized controlled trials (RCTs) published in the Cochrane Database of Systematic Reviews in 2019 found that there was no significant difference in the overall response rate, mortality, or adverse events between aminoglycosides and tigecycline for the treatment of cUTI. However, the analysis suggested that aminoglycosides may be more effective in eradicating Gram-negative pathogens, particularly Pseudomonas aeruginosa, compared to tigecycline.\n\nAnother meta-",
                "Plazomicin and colistin are both antibiotics used in the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), but the evidence comparing the two drugs in terms of efficacy, safety, and optimal use is still evolving.\n\nPlazomicin is a new generation aminoglycoside with improved activity against CRE compared to older aminoglycosides. A phase 3 clinical trial, named FORTA (Forta-I and Forta-II), evaluated the efficacy and safety of plazomicin compared to meropenem or colistin in the treatment of complicated urinary tract infections (cUTI) and bloodstream infections (BSI) caused by CRE. The results of this trial showed that plazomicin was non-inferior to meropenem and colist",
                "Several studies have investigated the difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with infections caused by Carbapenem-resistant Enterobacterales (CRE), including those caused by carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa. The results of these studies have been inconsistent.\n\nSome studies have reported no significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy. For example, a retrospective study of 112 patients with CRE infections published in the Journal of Antimicrobial Chemotherapy found no significant difference in 28-day mortality between the two groups (18.2%",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE), including Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is still emerging, and the optimal approach is not yet fully established.\n\nSeveral studies have investigated the efficacy and safety of cefiderocol monotherapy compared to combination therapy in the treatment of CRE infections. Here are some key studies:\n\n1. SAVANNA Trial: The SAVANNA (CEFIDERCOL vs. COLISTIN/IMPIPENEM for the Treatment of Carbapenem-resistant Enterobacteri",
                "I apologize for any confusion, but I cannot provide you with the specific results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections as there seems to be no published study with that exact title and inclusion criteria.\n\nHowever, there have been several studies investigating the effectiveness and safety of ceftolozane-tazobactam compared to polymyxins or aminoglycosides in the treatment of monomicrobial MDR/XDR P. aeruginosa infections.\n\nA systematic review and meta-analysis of 11 studies published in the Journal of Antimicrobial Chemotherapy in 2019 found that ceftolozane-tazobact",
                "CRPA (Carbapenem-resistant Pseudomonas aeruginosa) infections can be challenging to treat due to the resistance of the bacteria to many antibiotics. Polymyxins, aminoglycosides, and fosfomycin are commonly used antibiotics for the treatment of CRPA infections.\n\nPolymyxins (colistin and polymyxin E) are considered the first-line antibiotics for severe CRPA infections due to their gram-negative bactericidal activity. Polymyxins bind to the lipid A component of the bacterial cell wall, disrupting the membrane and leading to bacterial death. However, polymyxins can cause nephrotoxicity and neurotoxicity, which can limit their use.\n\nAminoglycosides (gentamicin, to",
                "For patients with CRAB (Clostridioides difficile-related complications, including severe colitis, fulminant colitis, megacolon, and toxic megacolon) who are susceptible to sulbactam and have healthcare-associated pneumonia (HAP) or ventilator-associated pneumonia (VAP), the suggested treatment may depend on the severity of the infection and the patient's overall condition.\n\nFirst-line antibiotic therapy for HAP/VAP caused by Clostridioides difficile typically includes metronidazole, vancomycin, or fidaxomicin for the treatment of the underlying C. difficile infection. However, these antibiotics may not be effective against HAP/VAP complications.\n\nIn such cases, empiric antimicrobial therapy for H",
                "Cefiderocol is a siderophore cephalosporin antibiotic that is approved for the treatment of complicated intra-abdominal infections, including those caused by susceptible Gram-negative bacteria. CRAB (community-acquired or nosocomial-acquired, recurrent or persistent, intra-abdominal infections) is a specific type of intra-abdominal infection.\n\nSeveral studies have evaluated the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections. Here are some key findings:\n\n1. A randomized, double-blind, multicenter study compared cefiderocol to meropenem in the treatment of complicated intra-abdominal infections, including CRAB. The study showed that cefiderocol was non-inferior to meropenem",
                "Polymyxin-carbapenem combination therapy has been studied as a potential treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections based on the synergistic effect of both antibiotics. Here are some observational studies that have investigated the effectiveness of this combination therapy for CRAB infections:\n\n1. A retrospective study by Liu et al. (2018) analyzed the medical records of 112 patients with CRAB infections who received polymyxin-carbapenem combination therapy. The study reported a 91.1% overall response rate, with a 78.6% success rate in eradicating the infection. The authors concluded that polymyxin-carbapenem combination therapy is effective in treating CRAB infections.\n\n2.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections are a significant challenge in clinical microbiology due to the increasing resistance of these bacteria to commonly used antibiotics. Here are some general principles for antibiotic treatment in patients with CR-GNB infections:\n\n1. Identify the specific CR-GNB causing the infection through microbiological culture and susceptibility testing. This information is crucial for selecting the most effective antibiotic.\n2. Choose an antibiotic with in vitro activity against the identified CR-GNB. This may include polymyxins (such as polymyxin B or E), aminoglycosides (such as amikacin or gentamicin), tigecycline, or other novel antibiotics.\n3. Consider the site of infection and the patient's clinical condition when",
                "Patients undergoing colorectal and liver transplant surgery require careful preoperative evaluation due to the complex nature of these procedures and the potential for complications. Here are some suggested screening approaches for these patients:\n\n1. Colorectal Transplant Surgery:\n- Preoperative assessment should include a thorough history and physical examination, with a focus on the gastrointestinal system.\n- Laboratory tests: Complete blood count, coagulation studies, electrolytes, liver function tests, and carcinoembryonic antigen (CEA) level.\n- Imaging studies: Colonoscopy or flexible sigmoidoscopy with biopsy if indicated, abdominal and pelvic CT or MRI to evaluate for any unsuspected lesions or metastases.\n- Infection screening: Hepatitis B and C serology, human immun",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Resistive-Escherichia coli (ESCR-E) undergoing colorectal surgery is not clear-cut and depends on several factors.\n\nThe European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Surgical Research Group (ESRG) published guidelines in 2017 recommending PAP for patients with active infections or colonization with multidrug-resistant organisms (including ESCR-E) if the infection is likely to spread during surgery. However, for asymptomatic colonization, the benefit of PAP is less clear.\n\nThe Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of",
                "Extensively drug-resistant Enterococci (ESCR-E) and extensively drug-resistant Pseudomonas aeruginosa (ESCR-PA) are bacteria that have developed resistance to most or all available antibiotics. The treatment of infections caused by these bacteria is a challenge, and the use of last-resort antibiotics should be reserved for specific cases.\n\nThe European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Society of Intensive Care Medicine and Anesthesiology (ESICM) have published guidelines on the management of infections caused by ESCR-E and ESCR-PA. According to these guidelines, the following antibiotics should be reserved for the treatment of infections caused by extensively resistant bacteria and not used routinely:\n\n1. Polymyxins",
                "Research protocols investigating the impact of targeted PAP (pneumococcal and other encapsulated bacteria prevention using antibiotics) in reducing post-transplant infections among Extended-Spectrum Cephalosporin Resistant-Enterococcus (ESCR-E) colonized Solid Organ Transplant (SOT) candidates should include the following elements:\n\n1. Study Design: The study design should be clearly stated, including the type of study (interventional, observational, etc.), the study population, and the study setting.\n2. Objectives: The study objectives should be clearly stated, including the primary and secondary endpoints.\n3. Inclusion and Exclusion Criteria: The inclusion and exclusion criteria should be clearly defined to ensure that the study population is appropriate for the research question.\n4. Intervention: The intervention should be clearly described, including the",
                "Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. The goal of PAP is to reduce the risk of surgical site infections (SSIs). In patients colonized with CRE, the risk of developing SSIs is increased due to the potential for carrying antibiotic-resistant bacteria. Therefore, targeted PAP with antibiotics effective against CRE can help reduce the risk of SSIs in these patients. However, the specific antibiotic choice and dosing regimen should be determined based on local guidelines and patient-specific factors, such as the type of surgery and patient allergies. It is also important to note that PAP should not replace the need for strict infection control measures to prevent the spread of CRE.",
                "Screening SOT (solid organ transplant) recipients for CRAB (chronic rejection, acute rejection, banff lesions) before surgery involves a comprehensive evaluation to assess the current status of the transplanted organ and the overall health of the recipient. Here are some good practices for screening SOT recipients for CRAB before surgery:\n\n1. Review of medical history: A thorough review of the recipient's medical history, including details of the transplant procedure, immunosuppressive therapy, and previous episodes of rejection, if any.\n\n2. Laboratory tests: A complete blood count (CBC), serum creatinine, liver function tests, and immunosuppressive drug levels should be checked.\n\n3. Imaging studies: Imaging studies such as ultrasound, CT scan, or MRI may be required to assess the size, function",
                "To investigate CRAB (Candida auris-related bloodstream infections) colonization and targeted PAP (positive blood culture identification and antimicrobial stewardship), the following types of clinical trials could be suggested:\n\n1. Prospective observational studies: These studies can be used to assess the prevalence and incidence of CRAB colonization in different patient populations and settings. They can also evaluate the effectiveness of targeted PAP in identifying CRAB infections and guiding antimicrobial therapy.\n2. Randomized controlled trials (RCTs): RCTs can be used to evaluate the efficacy and safety of interventions aimed at reducing CRAB colonization and preventing CRAB infections. For example, studies could investigate the use of decolonization protocols, such as chlorhexidine bathing or antifungal agents, to reduce CRAB",
                "In transplant surgery other than renal transplants, the suggested duration of post-anesthesia care unit (PACU) or post-operative recovery varies depending on the specific type of surgery and the individual patient's condition. Here are some general guidelines for some common non-renal transplant surgeries:\n\n1. Liver transplant: Patients are typically monitored in the ICU for 1-2 days and in the PACU for 1-2 days after liver transplant surgery.\n2. Heart transplant: Patients are typically monitored in the ICU for 1-2 weeks and in the PACU for 1-2 days after heart transplant surgery.\n3. Lung transplant: Patients are typically monitored in the ICU for 3-7 days and in the PACU for 1-2",
                "MDR-GNB (Multidrug-resistant Gram-negative bacteria) infections are a significant concern in solid organ transplant (SOT) recipients due to their increased susceptibility to infections and the potential for antibiotic resistance. The risk of MDR-GNB infections in SOT recipients varies depending on several factors, including the type of transplant, the underlying condition of the patient, and the exposure to healthcare environments.\n\nAccording to a systematic review and meta-analysis published in the Journal of Infection, the pooled incidence of MDR-GNB infections in SOT recipients was reported to be around 5-10%. However, the incidence can be higher in certain patient populations, such as those undergoing kidney transplantation or those with pre-existing conditions like diabetes or cystic fibrosis.\n\nMDR-GNB",
                "The identification of fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is important to reduce the risk of post-biopsy infections and potential development of antibiotic-resistant bacteria. Here are some suggested approaches to identify FQR-E carriers:\n\n1. Pre-biopsy urine culture: Obtain a clean-catch urine sample from the patient before the biopsy procedure. Culture the urine for Enterobacteriaceae and perform antimicrobial susceptibility testing, including fluoroquinolones. If the urine culture grows FQR-E, consider alternative antibiotic prophylaxis for the biopsy procedure.\n\n2. Rectal swab culture: Obtain a rectal sw",
                "A randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (Prostate Antigen Precipitation) versus culture-based PAP (Prostate Specific Antigen Prostatectomy) in patients undergoing Transrectal Ultrasound-Guided Prostate Biopsy (TRUSPB), particularly in fluoroquinolone-resistant (FQR) carriers, would provide data on the diagnostic accuracy and effectiveness of each method in detecting prostate cancer in this specific population.\n\nHowever, the outcome of such a trial would depend on the specific results of the study. Some possible outcomes could be:\n\n1. Ciprofloxacin PAP is more effective than culture-based PAP in detecting prostate cancer in FQR carriers. This could be due to the ability of ciproflo",
                "Urinary colonization with MDR-GNB has been identified as a risk factor for postoperative infections in patients undergoing urologic surgery. MDR-GNB are bacteria that are resistant to multiple antibiotics, making infections caused by these bacteria more difficult to treat.\n\nStudies have shown that the presence of MDR-GNB in urine samples obtained before urologic surgery is associated with an increased risk of postoperative infections. For example, a study published in the Journal of Urology found that patients with preoperative urinary colonization with MDR-GNB were more likely to develop postoperative infections than patients without colonization.\n\nThe mechanism by which urinary colonization with MDR-GNB increases the risk of postoperative infections is not fully understood, but it is believed to be related to the fact that these bacteria can establish",
                "Reducing surgical site infections (SSIs) requires a comprehensive approach that addresses various factors before, during, and after surgery. Here are some key elements of a comprehensive approach to reducing SSIs:\n\n1. Preoperative preparation:\n   a. Proper patient selection and optimization\n   b. Timely and appropriate antibiotic prophylaxis\n   c. Management of comorbid conditions\n   d. Proper hair removal and skin preparation\n\n2. Operating room environment:\n   a. Proper temperature and ventilation\n   b. Use of sterile equipment and instruments\n   c. Proper use of surgical drapes and gowns\n   d. Surgical team education and training\n\n3. Surgical technique:\n   a. Proper surgical site preparation and sterile technique\n   b. Use of closed-system insufflation devices during",
                "Standard Operating Procedures (SOPs) for sampling site techniques and microbiological methods are essential to ensure consistency, accuracy, and reliability in the collection and analysis of microbiological samples. Here are some recommended practices for developing SOPs in these areas:\n\n1. Sampling Site Techniques:\n\na. Define the sampling site and selection criteria.\nb. Establish a schedule for sampling.\nc. Describe the equipment required for sampling, such as sterile containers, sampling devices, and personal protective equipment.\nd. Outline the steps for collecting samples, including the number of samples to be taken, the method of collection, and the handling of the samples before transport to the laboratory.\ne. Provide instructions for documenting the sampling event, including recording the date, time, location, and environmental conditions.\nf. Establish procedures for dealing with contaminated or non-",
                "When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered to optimize the effectiveness of the antibiotic prophylaxis and minimize the risk of developing antibiotic resistance or adverse effects. Some of these factors include:\n\n1. Type and duration of the surgical procedure: The choice of antibiotic and the duration of administration should be based on the type and duration of the surgical procedure. For example, for clean-contaminated or contaminated procedures, longer durations of antibiotic administration may be required.\n2. Risk of CRE infection: The risk of CRE infection should be assessed based on the patient's medical history, comorbidities, and the prevalence of CRE in the hospital or community. Pat",
                "Colonization status refers to the presence of potentially harmful bacteria in the gastrointestinal tract that are not normally present in the body of an individual. In the context of solid organ transplantation (SOT), it is important to know the colonization status of a patient for several reasons:\n\n1. Infection risk: Patients undergoing SOT are at increased risk for infections due to the suppression of their immune system after transplantation. Colonized bacteria, particularly those that are multidrug-resistant, can cause serious infections, leading to complications and even death.\n2. Antibiotic prophylaxis: Knowing the colonization status of a patient can help guide the use of antibiotic prophylaxis to prevent infections caused by these bacteria. For example, patients who are colonized with certain bacteria may benefit from targeted antibiotic therapy before and"
            ],
            "additional prompt / no context": [
                "The evidence on the treatment of infections caused by third-generation cephalosporin-resistant bacteria (3GCRE) is organized through numerous studies, meta-analyses, and guidelines. These sources provide evidence on the effectiveness and safety of various antibiotics, including carbapenems, aminoglycosides, and polymyxins, among others. The Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) publish guidelines on the diagnosis and treatment of infections caused by 3GCRE. Additionally, the Centers for Disease Control and Prevention (CDC) provides recommendations based on the latest scientific evidence. It is important to note that the most effective treatment depends on the specific type and location of the infection, as well as the susceptibility patterns of the bacteria.",
                "Retrospective observational studies have shown that carbapenems are more effective than non-carbapenem antibiotics, including cephalosporins, quinolones, and aminoglycosides, in treating 3rd generation cephalosporin-resistant infections (3GCephRE). Carbapenems have a higher success rate in achieving microbiological and clinical cure. However, they are associated with higher costs and potential side effects. The choice of antibiotic should consider the specific infection, patient factors, and local resistance patterns.",
                "The studies comparing cephamycins (cefmetazole or flomoxef) to carbapenems for the treatment of 3GCephalosporin-resistant bloodstream infections (BSIs) have shown that cephamycins are less effective than carbapenems in terms of microbiological cure and clinical response. However, they may still be considered as an option in certain situations, such as when other alternatives are limited and the patient's condition is stable. It is important to note that individual patient outcomes may vary and that consultation with an infectious disease specialist is recommended for optimal management.",
                "The studies suggest that cephamycins and cefepime are comparable to carbapenems in terms of clinical cure rates for pyelonephritis caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). However, higher resistance rates to cephamycins and cefepime may require larger doses or alternative agents for effective treatment.",
                "Retrospective studies have shown that carbapenems are more effective than non-carbapenem antibiotics in treating complicated urinary tract infections (UTIs), particularly in cases of multidrug-resistant bacteria. However, carbapenems are associated with higher costs and potential side effects. The choice between carbapenems and non-carbapenem antibiotics depends on the specific clinical situation and local antibiotic resistance patterns.",
                "The RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3rd-generation cephalosporin-resistant (3GCephR) bacteria have shown that:\n\n1. Carbapenems (imipenem, meropenem) are effective in treating 3GCephR-IAI.\n2. Aminoglycosides (gentamicin, amikacin) in combination with beta-lactams (piperacillin-tazobactam, ceftriaxone-gentamicin) can be an alternative for carbapenem-unavailable settings.\n3. Fluoroquinolones (ciprofloxacin, levofloxacin) have shown variable efficacy and are generally less preferred due to resistance concerns",
                "The level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible Carbapenem-resistant Enterobacterales (CRE) is high, based on numerous clinical studies demonstrating superior clinical outcomes, such as higher microbiological and clinical cure rates, and reduced mortality. However, it's important to note that resistance patterns can vary, and the use of meropenem-vaborbactam should be individualized based on local resistance patterns and patient-specific factors.",
                "The evidence for the advantage of aminoglycosides over tigecycline for complicated urinary tract infections (cUTI) is inconclusive. Some studies suggest that aminoglycosides may have similar efficacy to tigecycline, while others suggest that tigecycline may have a slightly better safety profile. Ultimately, the choice between these antibiotics depends on individual patient factors and clinician preference.",
                "Plazomicin and colistin are both antibiotics used to treat infections caused by Carbapenem-resistant Enterobacterales (CRE). While both drugs have activity against CRE, the evidence regarding their comparative efficacy is limited.\n\nPlazomicin has been shown to have similar or slightly better in vitro activity against CRE compared to colistin. However, there are limited head-to-head clinical trials directly comparing the two drugs. The available data suggest that plazomicin may have a slightly better safety profile than colistin, particularly in terms of nephrotoxicity.\n\nOverall, while there is some evidence to suggest that plazomicin may be as effective as colistin for the treatment of CRE infections, more studies are needed to confirm this. The choice between the two drugs should be based on individual patient factors,",
                "Yes, there are studies suggesting that colistin-carbapenem combination therapy may have a lower 28-day mortality rate compared to colistin monotherapy in patients with Carbapenem-resistant Enterobacteriaceae (CRE) infections. However, the evidence is not definitive and more research is needed to confirm this. It's important to note that individual patient outcomes can vary greatly depending on the specific infection, underlying health conditions, and other factors. Always consult with a healthcare professional for medical advice.",
                "Cefiderocol is a siderophore cephalosporin with activity against carbapenem-resistant Enterobacterales (CRE). The FDA approved cefiderocol for the treatment of complicated urinary tract infections and pyelonephritis caused by susceptible Gram-negative microorganisms, including CRE, based on the results of the SISPIRIT trial. This trial demonstrated non-inferiority of cefiderocol monotherapy compared to meropenem-doripenem combination therapy in the treatment of complicated urinary tract infections caused by CRE. However, it's important to note that the clinical context, patient characteristics, and local resistance patterns should be considered when deciding between monotherapy and combination therapy for CRE infections. Consulting the latest guidelines and seeking advice from an infectious disease specialist is recommended.",
                "The retrospective cohort study found that ceftolozane-tazobactam was associated with a higher clinical cure rate (83.3%) compared to polymyxins or aminoglycosides (63.6%). Ceftolozane-tazobactam also had a lower mortality rate (13.3%) compared to polymyxins or aminoglycosides (26.7%). However, it's important to note that retrospective studies have limitations and more well-designed studies are needed to confirm these findings.",
                "For severe infections caused by CRPA (Carbapenem-resistant Pseudomonas aeruginosa), the recommended antibiotic regimens include:\n\n1. Polymyxins (e.g., polymyxin B or E) in combination with an aminoglycoside (e.g., gentamicin or tobramycin).\n2. Monotherapy with a newer polymyxin (e.g., meropenem-vaborbactam or imipenem-relebactam) if susceptible.\n3. Fosfomycin in combination with an aminoglycoside or a beta-lactam antibiotic if susceptible.\n\nThese combinations aim to provide synergistic activity against CRPA and improve treatment outcomes. Always consult local guidelines and susceptibility data before making specific treatment decisions",
                "For patients with CRAB (Carbapenem-resistant Acinetobacter baumannii) and susceptible to sulbactam but resistant to other antibiotics in the setting of HAP (Healthcare-associated pneumonia) or VAP (Ventilator-associated pneumonia), the suggested treatment options may include:\n\n1. Polymyxins (e.g., colistin or polymyxin E)\n2. Amikacin or other aminoglycosides if the organism is not extensively resistant\n3. Tigecycline or other glycylcyclines\n4. Fosfomycin\n5. Ceaselessly monitoring for the emergence of resistance and adjusting therapy accordingly.\n\nIt's essential to note that the choice of antibiotic depends on the specific suscept",
                "Cefiderocol is an antibiotic with activity against gram-negative bacteria, including those commonly responsible for CRAB (community-acquired or healthcare-associated carbapenem-resistant acinetobacter baumannii) infections. Several studies have shown that cefiderocol is effective in treating CRAB infections, with success rates similar to or even superior to those of other antibiotics such as colistin and tigecycline. However, it's important to note that individual patient outcomes may vary, and the choice of antibiotic should be based on the specific infection and patient's individual circumstances. Always consult the latest clinical guidelines and literature for the most up-to-date information.",
                "Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB (Carbapenem-resistant Acinetobacter baumannii) infections. However, high-quality randomized controlled trials are needed to provide stronger evidence of its efficacy and safety. The combination therapy may improve outcomes by synergistic effects of both antibiotics against carbapenem-resistant A. baumannii.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections require specific antibiotic treatment due to their resistance to common antibiotics. Here are some general principles for antibiotic treatment:\n\n1. Identify the specific CR-GNB causing the infection through laboratory testing.\n2. Choose an antibiotic that is active against the identified CR-GNB.\n3. Consider the site of infection and the patient's overall health when selecting an antibiotic.\n4. Administer the antibiotic intravenously (IV) in severe infections or when the patient cannot take oral medication.\n5. Monitor the patient closely for adverse effects and drug interactions.\n6. Consider using combination therapy for infections caused by certain CR-GNB, such as P. aeruginosa or A. baumannii.\n7. Ensure adequate dosing",
                "For patients undergoing colorectal transplant surgery, preoperative screening typically includes colonoscopy to assess for colon cancer or precancerous lesions. For liver transplant patients, screening may include ultrasound, alpha-fetoprotein (AFP) level measurement, and hepatitis serology to assess for liver disease and liver cancer. These recommendations may vary based on individual patient risk factors and guidelines from professional organizations. Always consult with a healthcare provider for specific recommendations.",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Cephalosporin-Resistant Enterococci (ESCR-E) undergoing colorectal surgery is controversial. Some guidelines suggest considering alternative antibiotics for PAP, while others recommend using a different class of antibiotics altogether, such as aminoglycosides or glycopeptides. Ultimately, the decision should be individualized based on the specific patient's risk factors and the local antibiotic resistance patterns. Consulting with an infectious disease specialist or a colon and rectal surgeon is recommended for optimal management.",
                "The antibiotics that should be reserved for the treatment of extensively resistant bacteria (such as extensively drug-resistant Mycobacterium tuberculosis or carbapenem-resistant Enterobacteriaceae) include:\n\n1. Polymyxins (e.g., colistin)\n2. Tigecycline\n3. Amikacin (for certain types of bacteria)\n4. Bedaquiline (for M. tuberculosis)\n5. Delamanid (for M. tuberculosis)\n\nThese antibiotics should not be used routinely for targeted PAP (pre-exposure prophylaxis) in Extensively Drug-Resistant-Tuberculosis (ESCR-TB) carriers due to their potential toxicity, limited availability, and the development of resistance with overuse. Instead",
                "Recommended components for research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates include:\n\n1. Study design: Randomized controlled trials (RCTs) or observational studies.\n2. Study population: ESCR-E colonized SOT candidates.\n3. Intervention: Targeted PAP (pre-transplant antimicrobial prophylaxis) with specific antibiotics.\n4. Comparator: Standard of care or placebo.\n5. Outcomes: Primary outcome - post-transplant infections; secondary outcomes - graft function, adverse events, and microbiological outcomes.\n6. Sample size: Based on the expected effect size and power analysis.\n7. Study duration: From pre-transplantation to post-transplantation follow-up.",
                "Yes, a recommendation can be issued for targeted PAP using non-carbapenem antibiotics for patients colonized with CRE before surgery to reduce the risk of surgical site infections caused by CRE. However, the specific antibiotic choice should be based on local resistance patterns and patient factors. Consult local guidelines and infectious disease specialists for the most appropriate antibiotic selection.",
                "A good practice for screening Solid Organ Transplant (SOT) recipients for CRAB (Chronic Renal Allograft Abolition) before surgery is to assess their renal function with regular serum creatinine levels and estimated glomerular filtration rate (eGFR). Additionally, monitoring for proteinuria, hematuria, and signs of allograft dysfunction is essential. If there are concerns, a renal biopsy may be necessary to confirm CRAB. Regular follow-ups with a nephrologist are recommended for close monitoring.",
                "To investigate CRAB (Clostridioides difficile-associated diarrhea) colonization and targeted PAP (proteasome activating protein), the panel would suggest designing randomized controlled trials (RCTs) with a placebo or active comparator arm. These trials should include adequate sample size, proper study design, and standardized endpoints to assess the efficacy and safety of targeted PAP in preventing CRAB colonization. Additionally, consider using biomarkers to objectively measure CRAB colonization and response to treatment.",
                "In transplant surgery other than renal transplant, the suggested duration of post-operative positive airway pressure (PAP) varies depending on the specific type of transplant and individual patient's condition. Generally, it ranges from a few days to several weeks. For example, in liver transplant, PAP may be used for a few days to help prevent respiratory complications. In heart-lung transplant, PAP may be required for several weeks to help the lungs adjust to the new organ. It's important to consult with the transplant team for specific recommendations.",
                "The risk of Multidrug-resistant Gram-negative bacterial (MDR-GNB) infections in solid organ transplant (SOT) recipients is relatively high due to the use of immunosuppressive medications. These infections can lead to serious complications such as sepsis, organ failure, and increased mortality. Common MDR-GNB pathogens include P. aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Prevention strategies include strict infection control measures, appropriate antibiotic prophylaxis, and close monitoring for signs of infection.",
                "The suggested approach to identify FQR-E carriers before TRUSPB includes:\n\n1. Obtaining a urine culture before the procedure.\n2. Sensitivity testing for fluoroquinolones in the urine culture result.\n3. Considering alternative antibiotics for prophylaxis if FQR-E is identified.\n\nIt's important to note that the decision to test for FQR-E should be based on local prevalence and individual patient risk factors. Consult local guidelines and infectious disease specialists for specific recommendations.",
                "The specific outcome of the trial you're referring to is not readily available in a clear and short answer format, as I would need to access the study's results to provide an accurate response. However, in general, non-blinded trials may be subject to bias, and comparing ciprofloxacin PAP (prostate antimicrobial prostatease) to culture-based PAP (transrectal ultrasound-guided prostate biopsy with conventional culture) in fluoroquinolone-resistant carriers could affect the results due to potential differences in detection rates and antimicrobial efficacy. For the most accurate information, I would recommend looking up the specific study or consulting a urology or infectious disease specialist.",
                "Urinary colonization with MDR-GNB is a significant risk factor for postoperative infections in patients undergoing urologic surgery. These bacteria can cause infections during or after the procedure, leading to increased morbidity and mortality. Preoperative urine screening and appropriate antibiotic prophylaxis can help reduce the risk of these infections.",
                "A comprehensive approach to reducing surgical site infections (SSIs) includes:\n\n1. Preoperative preparation: Optimizing the patient's health, proper wound preparation, and prophylactic antibiotics.\n2. Intraoperative measures: Sterile environment, proper surgical technique, and use of sterile instruments.\n3. Postoperative care: Wound care, early ambulation, and appropriate use of drains and dressings.\n4. Infection control policies: Implementing standardized protocols, surveillance, and education for healthcare personnel.\n5. Patient selection and optimization: Addressing comorbidities and risk factors.\n6. Vaccination: Ensuring up-to-date vaccinations, especially for patients undergoing orthopedic surgery.\n7. Antimicrobial stewardship: Appropriate use of antibiotics to prevent and",
                "For standard operating procedures (SOPs) related to sampling site technique, it's important to follow these steps:\n\n1. Properly clean and prepare the sampling site.\n2. Use sterile equipment for sampling.\n3. Collect sufficient sample size.\n4. Transport samples to the lab in appropriate containers and at proper temperature.\n\nFor microbiological methods, SOPs should include:\n\n1. Properly handling and transporting samples.\n2. Using appropriate media for culturing.\n3. Incubating samples at the correct temperature and time.\n4. Identifying and reporting results according to established protocols.",
                "When choosing targeted PAP for CRE infections, consider the following factors:\n\n1. Type and site of surgery: The risk of surgical site infection (SSI) varies depending on the type and site of surgery.\n2. Patient risk factors: Factors such as age, comorbidities, and underlying conditions increase the risk of SSI.\n3. Type and susceptibility of CRE: The specific type and susceptibility of the CRE strain can influence the choice of antibiotic.\n4. Allergies and drug interactions: Patients may have allergies or drug interactions that limit the choice of antibiotics.\n5. Duration of antibiotic therapy: The length of antibiotic therapy should be based on the type and site of surgery and the susceptibility of the CRE strain.\n6. Cost and availability: The cost and availability of antibiotics should",
                "Colonization of a patient with bacteria or other pathogens that can cause infections is important to know before solid organ transplantation (SOT) because:\n\n1. Transplant recipients are at increased risk for infections due to immunosuppressive therapy.\n2. Certain bacteria or viruses can cause severe infections in the transplanted organ or other parts of the body.\n3. Antibiotic prophylaxis or other preventive measures can be taken to reduce the risk of infection in the peri-transplant period.\n4. Some infections may require delaying or even canceling the transplant procedure.\n5. Knowing the colonization status can help guide the choice of antibiotic prophylaxis and other preventive measures."
            ],
            "no additional prompt / context": [
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including Bloodstream Infections (BSI), Urinary Tract Infections (UTI), pneumonia, and intra-abdominal infections (IAI). For BSI, the MERINO trial compared piperacillin-tazobactam with meropenem among patients with 3GCephRE BSI, but most studies were observational and showed no differences in mortality and other outcomes between BLBI and carbapenems. However, these data are limited by small sample sizes and potential bias. For cUTI in patients without septic shock, aminoglycosides or intravenous fosfomycin are conditionally recommended for short durations of therapy. Stepdown targeted therapy using old b-lactam/b-lactamase inhibitors, qu",
                "The retrospective observational studies comparing carbapenems with non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, for the treatment of 3GCephRE infections did not find any statistically significant differences between carbapenems and non-carbapenems. However, the sample sizes were small and residual differences between groups remained despite adjustment, leading to a moderate-risk to high-risk bias. Therefore, the evidence for the use of non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, as carbapenem-sparing regimens for the treatment of 3GCephRE infections is not strong.",
                "The studies evaluating cephamycins (cefmetazole or flomoxef) versus carbapenems for the treatment of 3GCephRE BSI showed conflicting results. In a large study of 389 patients, no association was found between targeted flomoxel therapy and mortality. However, when flomoxel's MIC were elevated within the susceptible range, flomoxel was associated with mortality compared with carbapenems. Another small study of 42 patients with dialysis access-related ESBL-Klebsiella spp. BSI showed higher mortality with targeted flomoxel compared with carbapenems, but most patients did not receive in vitro covering therapy in the first 5 days and appropriate adjustment was not possible considering the sample size. Overall, the evidence is insufficient to make a definitive recommendation",
                "None of the retrospective cohort studies found statistically significant differences between cephamycins and cefepime, and carbapenems for the treatment of pyelonephritis caused by 3GCephRE. All studies were at high risk of bias, and the sample sizes were very small, providing low-certainty evidence for the use of cephamycins and cefepime in this context.",
                "The retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated UTI found no significant difference in outcomes between the two groups. However, the sample sizes were small and residual differences between groups remained despite adjustment, indicating moderate-risk to high-risk bias. There was moderate-certainty evidence for aminoglycoside treatment of cUTI, but shorter durations are recommended due to the risk of nephrotoxicity after 7 days of therapy. Other carbapenem-sparing treatments, such as BLBLI, were evaluated in several studies, but none found statistically significant differences between BLBLI and carbapenems, supporting moderate-certainty evidence for BLBLI in the treatment of pyelonephritis caused by 3GCephRE. Overall, the evidence for the lack of",
                "The MERINO trial was a randomized controlled trial (RCT) that compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant Escherichia coli and K. pneumoniae. The study found that meropenem was non-inferior to piperacillin-tazobactam in terms of clinical cure and microbiological eradication [16]. However, there is conflicting evidence from observational studies regarding the use of older BLBII versus carbapenems for the treatment of IAI caused by 3GCephRE. Some observational studies suggest that older BLBII may be as effective as carbapenems, while others suggest that carbapenems may be more effective [17,18]. The use of carb",
                "Based on the small RCT (Tango-II) study mentioned in the context, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics. However, it is important to note that the sample size was small, and more research is needed to confirm these findings.",
                "The certainty of the evidence for an advantage of aminoglycosides over tigecycline for cUTI is moderate. The evidence includes studies that have shown higher survival rates with aminoglycosides compared with non-aminoglycoside regimens in patients with carbapenem and colistin-resistant K. pneumoniae with a prevalent respiratory source [127]. Another study observed better clinical cure with aminoglycosides compared with tigecycline for CR-K. pneumoniae infections with a urinary source [125]. However, there is insufficient evidence for other comparisons and other sources of infection. It is important to note that the use of aminoglycosides should be considered in the context of potential toxicity and the need for monitoring renal function.",
                "Based on the context provided, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The CRaCKle cohort study showed all-cause mortality at 28 days was lower with plazomicin combination therapy compared with colistin combination therapy, but the study was suspended after 2 years and there is currently insufficient evidence on plazomicin compared to colistin specifically for CRE.",
                "Based on the available evidence from the AIDA and OVERCOME trials, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections (p 0.24 in AIDA and p 0.25 in OVERCOME). However, it is important to note that these trials included mostly patients with CRAB infections, and the results may not be generalizable to all types of CRE infections. Additionally, the studies were suspended before their intended completion, limiting the available data on the long-term efficacy and safety of both treatment options. Therefore, more research is needed to establish the optimal treatment approach for CRE infections with colistin and carbapenems.",
                "Based on the available evidence, there is low-certainty evidence for the non-inferiority of cefercol monotherapy compared to other antibiotics for MBL-producing CRE infections. A subgroup analysis of patients with MBL-producing CR-GNB infections showed statistically non-significant higher cure and microbiological eradication rates for cefercol, but there was no significant difference in mortality. However, a post-hoc analysis by baseline pathogen revealed that the mortality difference was observed among patients with CRAB infections, but among patients with CR-K. pneumoniae, mortality at end of follow up was similar for cefercol and BAT.\n\nThere is no clinical experience evaluating the use of aztreonam monotherapy in the treatment of CRE infections.\n\nRegarding the use of combination",
                "The retrospective cohort study compared the outcomes of 100 patients treated with ceftolozane-tazobactam and 100 patients treated with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections. The study found that clinical care was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam. However, the study had a high risk of bias due to patient selection being unclear, baseline differences between groups not being fully adjusted, and data on carbapenem resistance not being provided.",
                "Based on the available evidence, it is recommended to treat severe infections caused by CRPA with two in vitro active drugs when using polymyxins, aminoglycosides, or fosfomycin (conditional recommendation for use, very low certainty of evidence). No specific combination recommendations can be provided.",
                "Based on the context provided, for patients with CRAB susceptible to sublactam and HAP/VAP, we suggest ampicillin-sublactam as the antibiotic of choice (conditional recommendation, low certainty of evidence).",
                "Based on the available evidence, the clinical and microbiological efficacies of cefiderocol versus other antibiotics in treating CRAB infections are similar. However, there is low-certainty evidence suggesting that cefiderocol may be non-inferior to other antibiotics for MBL-producing CRE infections, but this conclusion is based on small subgroup analyses. There is no clinical experience evaluating the use of aztreonam monotherapy in the treatment of CRE infections. Cefiderocol has shown inconclusive results in clinical trials compared to BAT and meropenem. Given the limited information available to date, it is recommended to use cefiderocol with caution and consider other treatment options for CRAB infections. Other antibiotics, such as aminoglycosides and tetracyclines, have shown inconclusive data in small ret",
                "Several observational studies have assessed the combination of polymyxins and carbapenems for CRAB infections, but the results are inconsistent. Some studies showed a significant association between the use of the combination and improved survival or clinical cure [198, 235, 247], while others did not [199, 244]. However, many of these studies included patients treated with a polymyxin-carbapenem combination in a larger group of patients treated with different combination therapies, making it difficult to assess the effects of a specific combination regimen.\n\n         It is important to note that high-certainty evidence against carbapenem-polymyxin combination therapies for CRAB infections comes from randomized controlled trials (RCTs), which contribute to a large body of evidence against the use of these combinations [",
                "1. Antibiotic stewardship considerations are important in the treatment of CR-GNB infections.\n2. The current guidelines recommend targeting specific pathogens with appropriate antibiotics, especially for patients considered at high risk for CR-GNB infections during the empirical treatment phase.\n3. For CR-GNB that are resistant to all b-lactams, testing against new BLBLI and polymyxins is recommended.\n4. Follow-up cultures are recommended in case of treatment failure, especially for CR-GNB, to detect resistance development.\n5. For pan-resistant CR-GNB, the least resistant antibiotic/s should be selected based on MICs relative to the breakpoints, but mainly optimal source control is crucial.\n6. Carbapenem-sparing therapy can be considered for non-severe",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery, according to the local epidemiology. This is a conditional recommendation with low certainty of evidence. It might also be a good practice to screen all SOT recipients for ESCR-E before surgery, according to the local epidemiology. The choice of targeted vs. universal screening should be based on local work organization and integrated within diagnostic and antibiotic stewardship guidance. Changes in screening and PAP policies should be based on local epidemiology, microbiological capacity, locally available financial resources, and patient's risk factors for ESCR-E acquisition. A cut-off for considering changes in antibiotic treatment according to local resistance preval",
                "Based on the evidence presented in the context, a conditional recommendation for use of targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery is made, with a low certainty of evidence. This recommendation is based on two studies, one of which was a multicenter, non-randomized, non-blinded interventional study that showed a potential benefit of etapenem use in reducing postoperative infections in ESCR-E carriers undergoing colorectal surgery [41]. The other study was a retrospective analysis of 100 ESCR-E colonized LTR in France that showed higher rates of ESCR-E postoperative infections among LTR receiving routine PAP compared with targeted PAP [32]. However, the evidence is of low certainty due to the observational study design and the lack",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. The use of carbapenems should also be limited if other antibiotic options are available against ESCR-E.",
                "1. Postsurgical monitoring of antibiotic resistance: This includes conducting rectal cultures for CRE colonization, especially if carbapenem-based PAP is used.\n        2. Reporting antimicrobial susceptibility: Researchers should report antimicrobial susceptibility results according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines.\n        3. Trial design considerations: The trial design should consider the local burden of ESCR-E and patient-related risk factors for carrier status.\n        4. High-risk surgical procedures: Clinical trials should be designed in ESCR-E carriers undergoing high-risk surgical procedures, such as major cardiothoracic surgery, pancreatic surgery, major oncologic general surgery, or gynecologic surgery.",
                "Based on the current evidence, no definitive recommendation can be issued for or against targeted PAP for patients who are colonized with CRE before surgery. The available evidence includes two retrospective studies with moderate and high risk of bias, respectively, and there is a need for well-designed clinical trials to evaluate the effectiveness, applicability, and safety of targeted PAP in CRE carriers undergoing SOT and other high-risk surgical procedures. These trials should consider rectal culture results, the limited number of options for treating CRE infections, and resistance monitoring to detect emerging resistance to the regimens used for targeted PAP.",
                "It might be a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology (ungraded good practice statement). Any change in procedures should follow a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards, considering a prevalence >=10% as a cut-off for implementation evaluation (based on previous recommendation). The choice of targeted versus universal screening should be based on the local work organization and integrated within antibiotic and diagnostic stewardship guidance. The knowledge of the colonization status of the patient before SOT is essential for early implementation of infection control procedures.",
                "The panel suggests designing clinical trials to investigate the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in clinical trials. These trials should consider rectal culture results, the limited number of options for treating CRE infections, and resistance monitoring to detect emerging resistance to the regimens used for targeted PAP. Clinical trials of targeted PAP should also follow antimicrobial stewardship principles.",
                "Based on the context provided, the suggested duration of PAP in transplant surgery other than renal transplant is 48-72 hours, according to some expert recommendations. However, it is important to note that there is currently no formal consensus on PAP duration in transplant surgery beyond renal transplant, and further research is needed to investigate the clinical impact of shorter versus longer PAP durations. Additionally, the duration of targeted PAP should align with current recommendations by international societies such as the Infectious Diseases Society of America, American Society of Health-System Pharmacists, Surgical Infection Society, and Society for Healthcare Epidemiology of America. These societies consistently give indication for PAP discontinuation within 24 hours after surgery.",
                "The risk of MDR-GNB infections in solid organ transplant (SOT) recipients varies depending on the type of organ transplanted and the geographic area. According to available data, SSIs are a common issue in SOT recipients, with highest rates observed for intestinal, liver, and pancreas transplantation. Intra-abdominal infections, especially in the early post-transplant period, are a significant concern for liver transplant recipients (LTR), with the risk of ESBL-E and CRKP infections ranging from 6% to 13% and 3% and 10%, respectively. Among non-fermenters, rates of CRAB and MDR PA infections in bloodstream infections (BSIs) can reach up to 63% and 52%, respectively. Post-SOT infections caused",
                "Based on the context provided, it is recommended to perform rectal screening to identify FQR-E carriers before TRUSPB. This is a conditional recommendation with moderate certainty of evidence.",
                "The randomized, non-blinded, multicenter trial compared ciprofloxacin PAP versus culture-based PAP in 1288 patients undergoing TRUSPB, including 15.8% FQR carriers. The study showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for the culture-based PAP group compared to the ciprofloxacin PAP group. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers. However, the data are limited by the non-blinded design and the short follow-up to assess infectious complications. The trial did not specifically address the impact of culture",
                "The evidence suggests that patients with urinary colonization with MDR-GNB have a higher risk of postoperative infections, particularly SSIs, compared to noncolonized patients undergoing urologic surgery. However, there is a lack of large-scale studies directly comparing postoperative infections in MDR-GNB urinary carriers versus noncarriers. A small, prospective study found that 15% of postoperative infections in patients receiving targeted PAP based on preoperative urine cultures were caused by the same colonizing strain, compared to 9% in noncarriers. Further research is needed to identify the impact of MDR-GNB colonization and targeted PAP on postoperative infections in patients undergoing urologic surgery, as well as to determine the optimal targeted PAP for different MDR-GNB based on the type of urological procedure and",
                "The comprehensive approach required to reduce surgical site infections (SSIs) involves a combination of antibiotic-based interventions and best surgical practices. Antibiotic-based interventions include targeted preoperative antibiotic prophylaxis (PAP) for MDR Gram-negative bacteria (MDR-GNB) carriers, especially in areas with high burden and for high-risk surgery. Additionally, optimizing antibiotic stewardship initiatives is essential to monitor and contain the consequences of new prescription patterns, enhance surveillance protocols, improve local adherence to guidelines, and promote a multidisciplinary approach to target SSIs.\n\nBest surgical practices include minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, and managing patient comorbidities. Metagenomic studies assessing the effect of antibiotic treatment on the",
                "Based on the context provided, there is a recommendation for implementing rectal screening to identify Carbapenem-resistant Acinetobacter baumannii (CRAB) carriers before liver transplant surgery according to local epidemiology (conditional recommendation, low certainty of evidence). The choice of targeted versus universal screening should be based on local work organization and integrated within antibiotic and diagnostic stewardship guidance. Irrespective of the PAP, the knowledge of the colonization status before surgery is essential for the early implementation of infection control procedures.\n\nRegarding standard operating procedures related to sampling site technique and microbiological methods, the context suggests that evidence is limited on the impact of targeted PAP on infectious complications following urologic surgery in MDR-GNB carriers. Rectal colonization may not be informative, while urinary cultures are often obtained to treat asymptomatic bacter",
                "1. Consider the local epidemiology of CRE infections and the incidence of CRE SSIs in your institution.\n2. The choice of targeted PAP should take into consideration the limited number of options available for the treatment of CRE infections, avoiding novel compounds that may be required for the treatment of postsurgical infections.\n3. Resistance monitoring should be performed through detection of MDR-CRE carriage after surgery and to detect emerging resistance to the regimens used for targeted PAP.\n4. In SSIs, the clonal relationship between MDR bacteria detected after surgery and preoperative colonizing bacteria should be determined, and both short- and long-term postsurgical colonization investigated.\n5. The impact of CRE rectal screening in high-risk surgeries should be evaluated through clinical trials.\n6. Antimicrobial stewardship principles should",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) because MDR-GNB (multidrug-resistant gram-negative bacteria) colonization has been associated with increased rates of postoperative infections and SSIs (surgical site infections) in various types of SOT procedures. Early detection of MDR-GNB carriers can inform contact precautions in SOT candidates and may be useful in guiding the treatment of postoperative infections. Additionally, targeted PAP (preoperative antimicrobial prophylaxis) can be considered for patients colonized with specific types of MDR-GNB, such as ESCR-E (extended-spectrum cephalosporin-resistant Enterobacteriaceae) or XDRPA (extensively drug-resistant Pseudomonas"
            ],
            "additional prompt / context": [
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including Bloodstream infections (BSI), Urinary Tract Infections (UTI), pneumonia, and intra-abdominal infections (IAI). For BSI, the MERINO trial compared piperacillin-tazobactam with meropenem, but most studies showed no significant difference between groups. Observational data shows no differences in mortality and other outcomes between BLBI and carbapenems. For cUTI in patients without septic shock, aminoglycosides or intravenous fosfomycin are conditionally recommended. Stepdown targeted therapy using old b-lactam/b-lactamase inhibitors, quinolones, cotrimoxazole, or other antibiotics based on the susceptibility pattern is good clinical",
                "The retrospective observational studies did not find statistically significant differences between carbapenems and non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, in the treatment of 3GCephRE infections. However, the sample sizes were small and residual differences between groups remained despite adjustment, leading to moderate-risk to high-risk bias.",
                "The studies evaluating cephamycins (cefmetazole or flomoxef) versus carbapenems for the treatment of 3GCephRE BSI showed conflicting results. In a large study of 389 patients, no association was found between targeted flomoxel therapy and mortality. However, when flomoxel's MIC were elevated within the susceptible range, flomoxel was associated with mortality compared with carbapenems. Another small study of 42 patients with dialysis access-related ESBL-Klebsiella spp. BSI showed higher mortality with targeted flomoxel compared with carbapenems, but most patients did not receive in vitro covering therapy in the first 5 days and appropriate adjustment was not possible considering the sample size. Overall, the evidence is insufficient to make a definitive recommendation",
                "None of the retrospective cohort studies found statistically significant differences between cephamycins and cefepime, and carbapenems for the treatment of pyelonephritis caused by 3GCephRE. All studies were at high risk of bias, and the evidence provided low-certainty for the use of cephamycins and cefepime for this indication.",
                "The retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated UTI found no significant difference in outcomes between the two groups. However, the certainty of this evidence was moderate-risk to high-risk due to small sample sizes and residual differences between groups despite adjustment. There was moderate-certainty evidence for the use of aminoglycosides in the treatment of cUTI, but shorter durations are recommended due to the risk of nephrotoxicity after 7 days of therapy. Other carbapenem-sparing treatments, such as BLBLI, were also evaluated with moderate-certainty evidence supporting their use in the treatment of pyelonephritis caused by 3GCephRE.",
                "The MERINO trial was a randomized controlled trial (RCT) that compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant E. coli and K. pneumoniae. The study found that meropenem was non-inferior to piperacillin-tazobactam in terms of clinical cure and microbiological eradication. However, there was a higher incidence of adverse events in the meropenem group.\n\n        For IAI caused by 3GCephRE, there is limited evidence from RCTs. One study, PICO 1, compared cefotaxime with ceftriaxone and found no significant difference in clinical cure or microbiological eradication. Another study compared piperacillin",
                "Based on the small RCT (Tango-II) study, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics.",
                "The certainty of the evidence for an advantage of aminoglycosides over tigecycline for cUTI is moderate.",
                "Based on the context provided, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The CRaCKle cohort study showed all-cause mortality at 28 days was lower with plazomicin combination therapy compared to colistin combination therapy, but the study was suspended after 2 years due to enrolment difficulties and there is currently insufficient evidence on plazomicin compared to colistin specifically for CRE.",
                "Based on the available evidence from the AIDA and OVERCOME trials, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. (Moderate-certainty evidence)",
                "Based on the available evidence, there is low-certainty evidence for the non-inferiority of cefiderocol compared with other antibiotics for MBL-producing CRE infections. However, there is no clear evidence to recommend for or against the use of combination therapy with cefiderocol for CRE infections. The evidence is conflicting regarding the use of combination therapy versus monotherapy for CRE infections overall, with some studies suggesting better clinical outcomes with combination therapy, particularly in patients with more severe disease and when it includes more than one in vitro active antimicrobial. However, the evidence is of very low certainty due to the observational nature and high risk of bias of most studies, as well as the variable definitions of combination therapy.",
                "The retrospective cohort study reported higher clinical care (adjusted OR 2.63, 95% CI 1.31-5.30) and lower nephrotoxicity (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam compared with polymyxins or aminoglycosides. However, the study had a high risk of bias due to unclear patient selection, lack of adjustment for baseline differences between groups, and no data on carbapenem resistance.",
                "We recommend treating severe infections caused by CRPA with two in vitro active drugs when using polymyxins, aminoglycosides, or fosfomycin (conditional recommendation, very low certainty of evidence). No specific combination recommendations can be provided.",
                "Based on the context provided, for patients with CRAB susceptible to sulbactam and HAP/VAP, we suggest ampicillin-sublactam as the antibiotic of choice (conditional recommendation, low certainty of evidence).",
                "Based on the available evidence, we conclude on low-certainty evidence for the non-inferiority of cefiderocol compared to other antibiotics for MBL-producing CRE infections. However, there is limited information available to date, and we cannot make a definitive recommendation for or against the use of cefiderocol for CRAB infections.",
                "Several observational studies have shown an association between the use of polymyxin-carbapenem combinations and improved survival or clinical cure in CRAB infections. However, not all studies have reported positive results, and it's important to note that many of these studies included patients treated with various combination therapies, making it difficult to assess the specific effects of a polymyxin-carbapenem combination. High-certainty evidence against the use of carbapenem-polymyxin combinations for CRAB infections comes from randomized controlled trials. For patients with CRAB infections and a meropenem MIC <8 mg/L, carbapenem combination therapy using high-dose extended-infusion carbapenem dosing is considered good clinical practice.",
                "1. Antibiotic stewardship considerations are important in the treatment of CR-GNB infections.\n2. The current guidelines recommend targeting specific pathogens with appropriate antibiotics based on local epidemiology during the empirical treatment phase.\n3. For CR-GNB that are resistant to all b-lactams, testing against new BLBLI and polymyxins is recommended.\n4. Follow-up cultures are recommended in case of treatment failure to detect resistance development.\n5. For pan-resistant CR-GNB, the least resistant antibiotic/s should be selected based on MICs and optimal source control.\n6. Carbapenem-sparing therapy can be considered for non-severe infections and low-risk sources of infection.\n7. The use of carbapenems for infections caused by",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epidemiology (ungraded good practice statement).",
                "Based on the available evidence, we conditionally recommend targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery. This recommendation is based on low certainty of evidence due to the limited number of studies and their observational design. It is important to note that this recommendation applies specifically to colorectal surgery. For liver transplant surgery, the evidence is very low, and it might be a good practice to consider targeted PAP for all SOT recipients who are colonized with ESCR-E before surgery.",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. Carbapenems should also be limited if other antibiotic options are available against ESCR-E.",
                "1. Postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n3. Designing clinical trials in ESCR-E carriers undergoing high-risk surgical procedures, considering the local burden of ESCR-E and patient-related risk factors for carrier status.",
                "Based on the current evidence, no definitive recommendation can be issued for or against targeted PAP for patients who are colonized with CRE before surgery. However, it is recommended to design clinical trials to assess the impact of CRE rectal screening in high-risk surgeries, including the effectiveness, applicability, and safety of targeted PAP following antimicrobial stewardship principles. These trials should consider rectal culture results, the limited number of options for treating CRE infections, and resistance monitoring to detect emerging resistance to the regimens used for targeted PAP.",
                "It is a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology (ungraded good practice statement). Any change in procedures should follow a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards, considering a prevalence >=10% as a cut-off for implementation evaluation (previous recommendation). The choice of targeted versus universal screening should be based on the local work organization and integrated within antibiotic and diagnostic stewardship guidance. The knowledge of the colonization status of the patient before SOT is essential for early implementation of infection control procedures.",
                "The panel suggests designing clinical trials to compare the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in clinical trials.",
                "Based on current recommendations from IDSA/ASHP/SIS/SHEA and other international societies, PAP should be discontinued within 24 hours after surgery in patients colonized with MDR-GNB for transplant surgery other than renal transplant as well. However, in some cases, extending PAP duration to 48-72 hours may be considered according to the type of transplant. Further research is needed to investigate the clinical impact of shorter versus longer PAP in this population.",
                "The risk of MDR-GNB infections in SOT recipients ranges from 3% to 53%, with the highest rates observed for intestinal, liver, and pancreas transplantation. Intra-abdominal infections, particularly in the early post-transplant period, are common in liver transplant recipients, with a risk of ESBL and CRKP infections ranging from 6% to 13% and 3% to 10%, respectively. ESCR-E infections are the most common type of MDR-GNB infections in SOT recipients, accounting for up to 75% of MDR-GNB isolates. Among non-fermenters, rates of CRAB and MDR PA infections in bloodstream infections can reach up to 63% and 52%, respectively. Post-S",
                "We suggest rectal screening to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
                "The trial reported a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for patients receiving culture-based PAP compared to ciprofloxacin PAP. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers. However, the study was not formally included in the evidence review and has some limitations, including the non-blinded design and the short follow-up period. The trial suggests that culture-based PAP may be more effective in reducing post-TRUSPB infections in FQR carriers, but further high-quality trials are needed to confirm these findings.",
                "There is evidence suggesting an association between urinary colonization with MDR-GNB and postoperative infections in patients undergoing urologic surgery. However, further research is needed to identify the impact of MDR-GNB colonization and targeted preoperative antibiotic prophylaxis (PAP) based on preoperative cultures on postoperative infections. The optimal targeted PAP for different MDR-GNB should also be investigated according to the type of urological procedure and the local rates of antibiotic resistance. Important knowledge gaps and limitations include retrospective study designs, small sample sizes, lack of assessment of key outcomes, and heterogeneity of surgical settings, types of PAP, and timing of assessment of postoperative infections.",
                "A comprehensive approach to reduce SSIs requires a focus on both antibiotic-based interventions and best surgical practices. This includes minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, and managing patient comorbidities. Additionally, heightening stewardship initiatives are necessary to monitor and contain the consequences of new prescription patterns, enhance surveillance protocols, improve local adherence to guidelines, and promote a multidisciplinary approach.",
                "1. It is recommended to consider rectal culture results for clinical trials of targeted PAP for CRE carriers undergoing surgery.\n2. The choice of targeted PAP should take into consideration the limited number of options available for the treatment of CRE infections, avoiding novel compounds that may be required for the treatment of postsurgical infections.\n3. Resistance monitoring should be performed through detection of MDR-CNB carriage after surgery and to detect emerging resistance to the regimens used for targeted PAP.\n4. In SSIs, the clonal relationship between MDR bacteria detected after surgery and preoperative colonizing bacteria should be determined, and both short- and long-term postsurgical colonization investigated.\n5. Any change in screening procedures should follow a careful assessment of local prevalence of CRAB or CRE colonization and infection among patients admitted or transferred to the surgical w",
                "1. Limited options for treating CRE infections: The choice of targeted PAP should consider the limited number of available options for treating CRE infections.\n        2. Avoiding novel compounds: Novel compounds that may be required for the treatment of postsurgical inctions should be avoided in targeted PAP.\n        3. Rectal culture results: Clinical trials of targeted PAP should be designed considering rectal culture results.\n        4. Resistance monitoring: Resistance monitoring should be performed through detection of MDR-CRE carriage after surgery and to detect emerging resistance to the regimens used for targeted PAP.\n        5. Clonal relationship: The clonal relationship between MDR bacteria detected after surgery and preoperative colonizing bacteria should be determined.\n        6. Short- and long-term colonization: Both short- and long-term postsurgical colonization should be investigated",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) because this information can help in the early implementation of infection control procedures to reduce the risk of intrahospital and community spreading of multidrug-resistant germs (MDR-GNB). This knowledge can also inform contact precautions and may be taken into consideration when treating postoperative infections. The evidence suggests that MDR-GNB carriers, particularly those colonized with Extended-Spectrum Cephalosporin-Resistant Enterococci (ESCR-E), have an increased risk of postoperative infections and SSIs. Limited data are available for XDRPA colonization and occurrence of post-SOT infections, but it may be relevant to target PAP for colonization of non-CI sites such as respiratory colonization by XDRPA"
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.05825995970071625,
                    "2_gram": 0.1086544286689707,
                    "3_gram": 0.08245166342278999,
                    "4_gram": 0.05762861075592003
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.15950488055112882,
                        "recall": 0.49337001319598367,
                        "fmeasure": 0.2321360593614503
                    },
                    "rouge_L": {
                        "precision": 0.10627614184215597,
                        "recall": 0.3464475984983581,
                        "fmeasure": 0.15717844070388162
                    }
                },
                "METEOR": 0.23319947465371624,
                "BERTScore": {
                    "Precision": -0.05,
                    "Recall": 0.188,
                    "F1_measure": 0.066
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.07727498139803828,
                    "2_gram": 0.14304701539742642,
                    "3_gram": 0.11089397247759285,
                    "4_gram": 0.07784888694697885
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20930895927064935,
                        "recall": 0.48220175693478623,
                        "fmeasure": 0.2773765627831704
                    },
                    "rouge_L": {
                        "precision": 0.14217141211985482,
                        "recall": 0.3310637194145358,
                        "fmeasure": 0.18884870776000837
                    }
                },
                "METEOR": 0.2528374413158506,
                "BERTScore": {
                    "Precision": 0.031,
                    "Recall": 0.229,
                    "F1_measure": 0.129
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.08023266189096066,
                    "2_gram": 0.16094753220735217,
                    "3_gram": 0.16405560113445505,
                    "4_gram": 0.1365722464712515
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3143285657962836,
                        "recall": 0.7950191815751707,
                        "fmeasure": 0.4305455506917027
                    },
                    "rouge_L": {
                        "precision": 0.24043139042719952,
                        "recall": 0.6180994897127723,
                        "fmeasure": 0.33155306649986355
                    }
                },
                "METEOR": 0.48809491452576287,
                "BERTScore": {
                    "Precision": 0.203,
                    "Recall": 0.549,
                    "F1_measure": 0.37
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.11574504597205437,
                    "2_gram": 0.21826792608231743,
                    "3_gram": 0.21780518956361167,
                    "4_gram": 0.18187991794053332
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.4084973653300584,
                        "recall": 0.7432066076399131,
                        "fmeasure": 0.4858028410021094
                    },
                    "rouge_L": {
                        "precision": 0.33444356708124956,
                        "recall": 0.607196736041746,
                        "fmeasure": 0.3975871259803813
                    }
                },
                "METEOR": 0.5005442833565139,
                "BERTScore": {
                    "Precision": 0.308,
                    "Recall": 0.558,
                    "F1_measure": 0.428
                }
            }
        }
    },
    {
        "parameters": {
            "embedding model": "BAAI/bge-small-en-v1.5",
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 512,
            "overlap": 25,
            "top_k": 5,
            "max new tokens": 190,
            "re-ranking": 0,
            "top_n": 0
        },
        "queries": [
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the retrospective observational studies comparing carbapenems with non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, for the treatment of 3GCephRE infections?",
            "What was the finding of the studies evaluating cephamycins (cefmetazole or flomoxef) versus carbapenems for the treatment of 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated UTI?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "None of the studies found a significant difference in outcomes between carbapenems and non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, although some studies reported a trend in favour of carbapenems or non-carbapenem-sparing antibiotics, but the evidence was limited by small sample sizes and residual differences between groups despite adjustment.",
            "The studies found no significant difference in mortality between cephamycins and carbapenems, except for one study that found an association between flomoxef therapy and mortality when the MIC was elevated within the susceptible range, but the overall certainty of the evidence was very low due to limitations in study design and sample size.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found no significant differences in clinical cure and microbiological outcomes between carbapenems and non-carbapenem antibiotics, including BLBLI, which achieved similar outcomes to carbapenems, with moderate-certainty evidence.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study design, such as randomized controlled trials (RCTs), observational studies, or systematic reviews. RCTs are considered the gold standard for evaluating the efficacy and safety of new treatments, while observational studies can provide valuable real-world data on how a treatment is used in clinical practice.\n2. Clinical guidelines: Clinical guidelines provide evidence-based recommendations for the diagnosis, prevention, and treatment",
                "Retrospective observational studies have compared the use of carbapenems with non-carbapenem antibiotics, including cephalosporins, quinolones, and aminoglycosides, for the treatment of infections caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). The findings of these studies have suggested that carbapenems are generally more effective in achieving microbiological and clinical cure compared to non-carbapenem antibiotics.\n\nHowever, it is important to note that these studies have several limitations, including selection bias, lack of standardized definitions for infection and outcome, and potential confounding factors. Additionally, the emergence of carbapenem-resistant bacteria, such as carbapenem-resistant Enterobacterales (CRE), has challenged the use of carb",
                "Several studies have compared the effectiveness and safety of cephamycins (cefmetazole or flomoxef) and carbapenems for the treatment of 3rd generation cephalosporin-resistant bloodstream infections (3GCephRE BSIs). Here are some key findings from these studies:\n\n1. Efficacy: The studies suggest that both cephamycins and carbapenems have similar efficacy in the treatment of 3GCephRE BSIs. However, some studies have shown that carbapenems may have a slightly higher success rate in achieving microbiological and clinical cure.\n2. Safety: Cephamycins are generally considered to be less toxic than carbapenems. However, they may cause more frequent and severe diarrhea compared to carbapenems.\n3. Resistance: The emergence of resistance",
                "Several studies have compared the effectiveness and safety of cephamycins (cefotetan and ceftriaxone) and cefepime to carbapenems (imipenem and meropenem) in the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase producing Enterobacteriaceae (3GCephre).\n\nA systematic review and meta-analysis of 12 randomized controlled trials (RCTs) by Zhang et al. (2018) found that cephamycins and cefepime were non-inferior to carbapenems in terms of clinical cure rate, microbiological eradication rate, and adverse events. However, subgroup analysis suggested that cefepime might be superior to carbapenems in achieving microbiological eradication in patients with severe",
                "Retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated urinary tract infections (UTIs) have yielded conflicting results. Some studies suggest that carbapenems may be more effective in achieving microbiological and clinical cure, particularly in cases of multidrug-resistant pathogens or complicated UTIs caused by Gram-negative bacteria. However, other studies have not shown significant differences in outcomes between carbapenems and non-carbapenem antibiotics.\n\nOne meta-analysis of 12 retrospective studies found that carbapenems were associated with a higher microbiological cure rate (OR 1.35, 95% CI 1.05-1.73) and a lower risk of treatment failure (OR 0.58, 95% C",
                "Several randomized controlled trials (RCTs) have evaluated the effectiveness of various antibiotics for the treatment of intra-abdominal infections (IAIs) caused by third-generation cephalosporin-resistant Enterobacterales (3GCRE). Here are some key findings from these studies:\n\n1. Carbapenems: Carbapenems, such as imipenem, meropenem, and ertapenem, have shown superiority over older antibiotics like ampicillin-sulbactam and cefotaxime in the treatment of 3GCRE-caused IAIs. Carbapenems have a broader spectrum of activity against Gram-negative bacteria, including 3GCRE, and are associated with higher clinical cure rates and lower mortality rates.\n2. Fluoroquinolones",
                "Meropenem-vaborbactam (MVB) is a carbapenem-beta-lactamase inhibitor combination antibiotic that has shown activity against certain carbapenem-resistant Enterobacterales (CRE), including those producing NDM-1 and OXA-48-type carbapenemases. The advantage of MVB over best available treatment for susceptible CRE is supported by several studies with varying levels of evidence.\n\n1. Randomized Controlled Trials (RCTs): A few small RCTs have compared MVB to other antibiotics for the treatment of infections caused by susceptible CRE. For example, a multicenter, randomized, non-inferiority trial (NCT02929593) compared MVB to imipenem-relebactam",
                "The comparative effectiveness and safety of aminoglycosides versus tigecycline for the treatment of complex urinary tract infections (cUTI) have been studied in several clinical trials. However, the evidence is not clear-cut, and the results are inconsistent.\n\nA systematic review and meta-analysis of 13 randomized controlled trials (RCTs) published in the Cochrane Database of Systematic Reviews in 2019 found that there was no significant difference in the overall response rate, mortality, or adverse events between aminoglycosides and tigecycline for the treatment of cUTI. However, the analysis suggested that aminoglycosides may be more effective in eradicating Gram-negative pathogens, particularly Pseudomonas aeruginosa, compared to tigecycline.\n\nAnother meta-",
                "Plazomicin and colistin are both antibiotics used in the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), but the evidence comparing the two drugs in terms of efficacy, safety, and optimal use is still evolving.\n\nPlazomicin is a new generation aminoglycoside with improved activity against CRE compared to older aminoglycosides. A phase 3 clinical trial, named FORTA (Forta-I and Forta-II), evaluated the efficacy and safety of plazomicin compared to meropenem or colistin in the treatment of complicated urinary tract infections (cUTI) and bloodstream infections (BSI) caused by CRE. The results of this trial showed that plazomicin was non-inferior to meropenem and colist",
                "Several studies have investigated the difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with infections caused by Carbapenem-resistant Enterobacterales (CRE), including those caused by carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa. The results of these studies have been inconsistent.\n\nSome studies have reported no significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy. For example, a retrospective study of 112 patients with CRE infections published in the Journal of Antimicrobial Chemotherapy found no significant difference in 28-day mortality between the two groups (18.2%",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE), including Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is still emerging, and the optimal approach is not yet fully established.\n\nSeveral studies have investigated the efficacy and safety of cefiderocol monotherapy compared to combination therapy in the treatment of CRE infections. Here are some key studies:\n\n1. SAVANNA Trial: The SAVANNA (CEFIDERCOL vs. COLISTIN/IMPIPENEM for the Treatment of Carbapenem-resistant Enterobacteri",
                "I apologize for any confusion, but I cannot provide you with the specific results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections as there seems to be no published study with that exact title and inclusion criteria.\n\nHowever, there have been several studies investigating the effectiveness and safety of ceftolozane-tazobactam compared to polymyxins or aminoglycosides in the treatment of monomicrobial MDR/XDR P. aeruginosa infections.\n\nA systematic review and meta-analysis of 11 studies published in the Journal of Antimicrobial Chemotherapy in 2019 found that ceftolozane-tazobact",
                "CRPA (Carbapenem-resistant Pseudomonas aeruginosa) infections can be challenging to treat due to the resistance of the bacteria to many antibiotics. Polymyxins, aminoglycosides, and fosfomycin are commonly used antibiotics for the treatment of CRPA infections.\n\nPolymyxins (colistin and polymyxin E) are considered the first-line antibiotics for severe CRPA infections due to their gram-negative bactericidal activity. Polymyxins bind to the lipid A component of the bacterial cell wall, disrupting the membrane and leading to bacterial death. However, polymyxins can cause nephrotoxicity and neurotoxicity, which can limit their use.\n\nAminoglycosides (gentamicin, to",
                "For patients with CRAB (Clostridioides difficile-related complications, including severe colitis, fulminant colitis, megacolon, and toxic megacolon) who are susceptible to sulbactam and have healthcare-associated pneumonia (HAP) or ventilator-associated pneumonia (VAP), the suggested treatment may depend on the severity of the infection and the patient's overall condition.\n\nFirst-line antibiotic therapy for HAP/VAP caused by Clostridioides difficile typically includes metronidazole, vancomycin, or fidaxomicin for the treatment of the underlying C. difficile infection. However, these antibiotics may not be effective against HAP/VAP complications.\n\nIn such cases, empiric antimicrobial therapy for H",
                "Cefiderocol is a siderophore cephalosporin antibiotic that is approved for the treatment of complicated intra-abdominal infections, including those caused by susceptible Gram-negative bacteria. CRAB (community-acquired or nosocomial-acquired, recurrent or persistent, intra-abdominal infections) is a specific type of intra-abdominal infection.\n\nSeveral studies have evaluated the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections. Here are some key findings:\n\n1. A randomized, double-blind, multicenter study compared cefiderocol to meropenem in the treatment of complicated intra-abdominal infections, including CRAB. The study showed that cefiderocol was non-inferior to meropenem",
                "Polymyxin-carbapenem combination therapy has been studied as a potential treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections based on the synergistic effect of both antibiotics. Here are some observational studies that have investigated the effectiveness of this combination therapy for CRAB infections:\n\n1. A retrospective study by Liu et al. (2018) analyzed the medical records of 112 patients with CRAB infections who received polymyxin-carbapenem combination therapy. The study reported a 91.1% overall response rate, with a 78.6% success rate in eradicating the infection. The authors concluded that polymyxin-carbapenem combination therapy is effective in treating CRAB infections.\n\n2.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections are a significant challenge in clinical microbiology due to the increasing resistance of these bacteria to commonly used antibiotics. Here are some general principles for antibiotic treatment in patients with CR-GNB infections:\n\n1. Identify the specific CR-GNB causing the infection through microbiological culture and susceptibility testing. This information is crucial for selecting the most effective antibiotic.\n2. Choose an antibiotic with in vitro activity against the identified CR-GNB. This may include polymyxins (such as polymyxin B or E), aminoglycosides (such as amikacin or gentamicin), tigecycline, or other novel antibiotics.\n3. Consider the site of infection and the patient's clinical condition when",
                "Patients undergoing colorectal and liver transplant surgery require careful preoperative evaluation due to the complex nature of these procedures and the potential for complications. Here are some suggested screening approaches for these patients:\n\n1. Colorectal Transplant Surgery:\n- Preoperative assessment should include a thorough history and physical examination, with a focus on the gastrointestinal system.\n- Laboratory tests: Complete blood count, coagulation studies, electrolytes, liver function tests, and carcinoembryonic antigen (CEA) level.\n- Imaging studies: Colonoscopy or flexible sigmoidoscopy with biopsy if indicated, abdominal and pelvic CT or MRI to evaluate for any unsuspected lesions or metastases.\n- Infection screening: Hepatitis B and C serology, human immun",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Resistive-Escherichia coli (ESCR-E) undergoing colorectal surgery is not clear-cut and depends on several factors.\n\nThe European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Surgical Research Group (ESRG) published guidelines in 2017 recommending PAP for patients with active infections or colonization with multidrug-resistant organisms (including ESCR-E) if the infection is likely to spread during surgery. However, for asymptomatic colonization, the benefit of PAP is less clear.\n\nThe Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of",
                "Extensively drug-resistant Enterococci (ESCR-E) and extensively drug-resistant Pseudomonas aeruginosa (ESCR-PA) are bacteria that have developed resistance to most or all available antibiotics. The treatment of infections caused by these bacteria is a challenge, and the use of last-resort antibiotics should be reserved for specific cases.\n\nThe European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Society of Intensive Care Medicine and Anesthesiology (ESICM) have published guidelines on the management of infections caused by ESCR-E and ESCR-PA. According to these guidelines, the following antibiotics should be reserved for the treatment of infections caused by extensively resistant bacteria and not used routinely:\n\n1. Polymyxins",
                "Research protocols investigating the impact of targeted PAP (pneumococcal and other encapsulated bacteria prevention using antibiotics) in reducing post-transplant infections among Extended-Spectrum Cephalosporin Resistant-Enterococcus (ESCR-E) colonized Solid Organ Transplant (SOT) candidates should include the following elements:\n\n1. Study Design: The study design should be clearly stated, including the type of study (interventional, observational, etc.), the study population, and the study setting.\n2. Objectives: The study objectives should be clearly stated, including the primary and secondary endpoints.\n3. Inclusion and Exclusion Criteria: The inclusion and exclusion criteria should be clearly defined to ensure that the study population is appropriate for the research question.\n4. Intervention: The intervention should be clearly described, including the",
                "Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. The goal of PAP is to reduce the risk of surgical site infections (SSIs). In patients colonized with CRE, the risk of developing SSIs is increased due to the potential for carrying antibiotic-resistant bacteria. Therefore, targeted PAP with antibiotics effective against CRE can help reduce the risk of SSIs in these patients. However, the specific antibiotic choice and dosing regimen should be determined based on local guidelines and patient-specific factors, such as the type of surgery and patient allergies. It is also important to note that PAP should not replace the need for strict infection control measures to prevent the spread of CRE.",
                "Screening SOT (solid organ transplant) recipients for CRAB (chronic rejection, acute rejection, banff lesions) before surgery involves a comprehensive evaluation to assess the current status of the transplanted organ and the overall health of the recipient. Here are some good practices for screening SOT recipients for CRAB before surgery:\n\n1. Review of medical history: A thorough review of the recipient's medical history, including details of the transplant procedure, immunosuppressive therapy, and previous episodes of rejection, if any.\n\n2. Laboratory tests: A complete blood count (CBC), serum creatinine, liver function tests, and immunosuppressive drug levels should be checked.\n\n3. Imaging studies: Imaging studies such as ultrasound, CT scan, or MRI may be required to assess the size, function",
                "To investigate CRAB (Candida auris-related bloodstream infections) colonization and targeted PAP (positive blood culture identification and antimicrobial stewardship), the following types of clinical trials could be suggested:\n\n1. Prospective observational studies: These studies can be used to assess the prevalence and incidence of CRAB colonization in different patient populations and settings. They can also evaluate the effectiveness of targeted PAP in identifying CRAB infections and guiding antimicrobial therapy.\n2. Randomized controlled trials (RCTs): RCTs can be used to evaluate the efficacy and safety of interventions aimed at reducing CRAB colonization and preventing CRAB infections. For example, studies could investigate the use of decolonization protocols, such as chlorhexidine bathing or antifungal agents, to reduce CRAB",
                "In transplant surgery other than renal transplants, the suggested duration of post-anesthesia care unit (PACU) or post-operative recovery varies depending on the specific type of surgery and the individual patient's condition. Here are some general guidelines for some common non-renal transplant surgeries:\n\n1. Liver transplant: Patients are typically monitored in the ICU for 1-2 days and in the PACU for 1-2 days after liver transplant surgery.\n2. Heart transplant: Patients are typically monitored in the ICU for 1-2 weeks and in the PACU for 1-2 days after heart transplant surgery.\n3. Lung transplant: Patients are typically monitored in the ICU for 3-7 days and in the PACU for 1-2",
                "MDR-GNB (Multidrug-resistant Gram-negative bacteria) infections are a significant concern in solid organ transplant (SOT) recipients due to their increased susceptibility to infections and the potential for antibiotic resistance. The risk of MDR-GNB infections in SOT recipients varies depending on several factors, including the type of transplant, the underlying condition of the patient, and the exposure to healthcare environments.\n\nAccording to a systematic review and meta-analysis published in the Journal of Infection, the pooled incidence of MDR-GNB infections in SOT recipients was reported to be around 5-10%. However, the incidence can be higher in certain patient populations, such as those undergoing kidney transplantation or those with pre-existing conditions like diabetes or cystic fibrosis.\n\nMDR-GNB",
                "The identification of fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is important to reduce the risk of post-biopsy infections and potential development of antibiotic-resistant bacteria. Here are some suggested approaches to identify FQR-E carriers:\n\n1. Pre-biopsy urine culture: Obtain a clean-catch urine sample from the patient before the biopsy procedure. Culture the urine for Enterobacteriaceae and perform antimicrobial susceptibility testing, including fluoroquinolones. If the urine culture grows FQR-E, consider alternative antibiotic prophylaxis for the biopsy procedure.\n\n2. Rectal swab culture: Obtain a rectal sw",
                "A randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (Prostate Antigen Precipitation) versus culture-based PAP (Prostate Specific Antigen Prostatectomy) in patients undergoing Transrectal Ultrasound-Guided Prostate Biopsy (TRUSPB), particularly in fluoroquinolone-resistant (FQR) carriers, would provide data on the diagnostic accuracy and effectiveness of each method in detecting prostate cancer in this specific population.\n\nHowever, the outcome of such a trial would depend on the specific results of the study. Some possible outcomes could be:\n\n1. Ciprofloxacin PAP is more effective than culture-based PAP in detecting prostate cancer in FQR carriers. This could be due to the ability of ciproflo",
                "Urinary colonization with MDR-GNB has been identified as a risk factor for postoperative infections in patients undergoing urologic surgery. MDR-GNB are bacteria that are resistant to multiple antibiotics, making infections caused by these bacteria more difficult to treat.\n\nStudies have shown that the presence of MDR-GNB in urine samples obtained before urologic surgery is associated with an increased risk of postoperative infections. For example, a study published in the Journal of Urology found that patients with preoperative urinary colonization with MDR-GNB were more likely to develop postoperative infections than patients without colonization.\n\nThe mechanism by which urinary colonization with MDR-GNB increases the risk of postoperative infections is not fully understood, but it is believed to be related to the fact that these bacteria can establish",
                "Reducing surgical site infections (SSIs) requires a comprehensive approach that addresses various factors before, during, and after surgery. Here are some key elements of a comprehensive approach to reducing SSIs:\n\n1. Preoperative preparation:\n   a. Proper patient selection and optimization\n   b. Timely and appropriate antibiotic prophylaxis\n   c. Management of comorbid conditions\n   d. Proper hair removal and skin preparation\n\n2. Operating room environment:\n   a. Proper temperature and ventilation\n   b. Use of sterile equipment and instruments\n   c. Proper use of surgical drapes and gowns\n   d. Surgical team education and training\n\n3. Surgical technique:\n   a. Proper surgical site preparation and sterile technique\n   b. Use of closed-system insufflation devices during",
                "Standard Operating Procedures (SOPs) for sampling site techniques and microbiological methods are essential to ensure consistency, accuracy, and reliability in the collection and analysis of microbiological samples. Here are some recommended practices for developing SOPs in these areas:\n\n1. Sampling Site Techniques:\n\na. Define the sampling site and selection criteria.\nb. Establish a schedule for sampling.\nc. Describe the equipment required for sampling, such as sterile containers, sampling devices, and personal protective equipment.\nd. Outline the steps for collecting samples, including the number of samples to be taken, the method of collection, and the handling of the samples before transport to the laboratory.\ne. Provide instructions for documenting the sampling event, including recording the date, time, location, and environmental conditions.\nf. Establish procedures for dealing with contaminated or non-",
                "When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered to optimize the effectiveness of the antibiotic prophylaxis and minimize the risk of developing antibiotic resistance or adverse effects. Some of these factors include:\n\n1. Type and duration of the surgical procedure: The choice of antibiotic and the duration of administration should be based on the type and duration of the surgical procedure. For example, for clean-contaminated or contaminated procedures, longer durations of antibiotic administration may be required.\n2. Risk of CRE infection: The risk of CRE infection should be assessed based on the patient's medical history, comorbidities, and the prevalence of CRE in the hospital or community. Pat",
                "Colonization status refers to the presence of potentially harmful bacteria in the gastrointestinal tract that are not normally present in the body of an individual. In the context of solid organ transplantation (SOT), it is important to know the colonization status of a patient for several reasons:\n\n1. Infection risk: Patients undergoing SOT are at increased risk for infections due to the suppression of their immune system after transplantation. Colonized bacteria, particularly those that are multidrug-resistant, can cause serious infections, leading to complications and even death.\n2. Antibiotic prophylaxis: Knowing the colonization status of a patient can help guide the use of antibiotic prophylaxis to prevent infections caused by these bacteria. For example, patients who are colonized with certain bacteria may benefit from targeted antibiotic therapy before and"
            ],
            "additional prompt / no context": [
                "The evidence on the treatment of infections caused by third-generation cephalosporin-resistant bacteria (3GCRE) is organized through numerous studies, meta-analyses, and guidelines. These sources provide evidence on the effectiveness and safety of various antibiotics, including carbapenems, aminoglycosides, and polymyxins, among others. The Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) publish guidelines on the diagnosis and treatment of infections caused by 3GCRE. Additionally, the Centers for Disease Control and Prevention (CDC) provides recommendations based on the latest scientific evidence. It is important to note that the most effective treatment depends on the specific type and location of the infection, as well as the susceptibility patterns of the bacteria.",
                "Retrospective observational studies have shown that carbapenems are more effective than non-carbapenem antibiotics, including cephalosporins, quinolones, and aminoglycosides, in treating 3rd generation cephalosporin-resistant infections (3GCephRE). Carbapenems have a higher success rate in achieving microbiological and clinical cure. However, they are associated with higher costs and potential side effects. The choice of antibiotic should consider the specific infection, patient factors, and local resistance patterns.",
                "The studies comparing cephamycins (cefmetazole or flomoxef) to carbapenems for the treatment of 3GCephalosporin-resistant bloodstream infections (BSIs) have shown that cephamycins are less effective than carbapenems in terms of microbiological cure and clinical response. However, they may still be considered as an option in certain situations, such as when other alternatives are limited and the patient's condition is stable. It is important to note that individual patient outcomes may vary and that consultation with an infectious disease specialist is recommended for optimal management.",
                "The studies suggest that cephamycins and cefepime are comparable to carbapenems in terms of clinical cure rates for pyelonephritis caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). However, higher resistance rates to cephamycins and cefepime may require larger doses or alternative agents for effective treatment.",
                "Retrospective studies have shown that carbapenems are more effective than non-carbapenem antibiotics in treating complicated urinary tract infections (UTIs), particularly in cases of multidrug-resistant bacteria. However, carbapenems are associated with higher costs and potential side effects. The choice between carbapenems and non-carbapenem antibiotics depends on the specific clinical situation and local antibiotic resistance patterns.",
                "The RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3rd-generation cephalosporin-resistant (3GCephR) bacteria have shown that:\n\n1. Carbapenems (imipenem, meropenem) are effective in treating 3GCephR-IAI.\n2. Aminoglycosides (gentamicin, amikacin) in combination with beta-lactams (piperacillin-tazobactam, ceftriaxone-gentamicin) can be an alternative for carbapenem-unavailable settings.\n3. Fluoroquinolones (ciprofloxacin, levofloxacin) have shown variable efficacy and are generally less preferred due to resistance concerns",
                "The level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible Carbapenem-resistant Enterobacterales (CRE) is high, based on numerous clinical studies demonstrating superior clinical outcomes, such as higher microbiological and clinical cure rates, and reduced mortality. However, it's important to note that resistance patterns can vary, and the use of meropenem-vaborbactam should be individualized based on local resistance patterns and patient-specific factors.",
                "The evidence for the advantage of aminoglycosides over tigecycline for complicated urinary tract infections (cUTI) is inconclusive. Some studies suggest that aminoglycosides may have similar efficacy to tigecycline, while others suggest that tigecycline may have a slightly better safety profile. Ultimately, the choice between these antibiotics depends on individual patient factors and clinician preference.",
                "Plazomicin and colistin are both antibiotics used to treat infections caused by Carbapenem-resistant Enterobacterales (CRE). While both drugs have activity against CRE, the evidence regarding their comparative efficacy is limited.\n\nPlazomicin has been shown to have similar or slightly better in vitro activity against CRE compared to colistin. However, there are limited head-to-head clinical trials directly comparing the two drugs. The available data suggest that plazomicin may have a slightly better safety profile than colistin, particularly in terms of nephrotoxicity.\n\nOverall, while there is some evidence to suggest that plazomicin may be as effective as colistin for the treatment of CRE infections, more studies are needed to confirm this. The choice between the two drugs should be based on individual patient factors,",
                "Yes, there are studies suggesting that colistin-carbapenem combination therapy may have a lower 28-day mortality rate compared to colistin monotherapy in patients with Carbapenem-resistant Enterobacteriaceae (CRE) infections. However, the evidence is not definitive and more research is needed to confirm this. It's important to note that individual patient outcomes can vary greatly depending on the specific infection, underlying health conditions, and other factors. Always consult with a healthcare professional for medical advice.",
                "Cefiderocol is a siderophore cephalosporin with activity against carbapenem-resistant Enterobacterales (CRE). The FDA approved cefiderocol for the treatment of complicated urinary tract infections and pyelonephritis caused by susceptible Gram-negative microorganisms, including CRE, based on the results of the SISPIRIT trial. This trial demonstrated non-inferiority of cefiderocol monotherapy compared to meropenem-doripenem combination therapy in the treatment of complicated urinary tract infections caused by CRE. However, it's important to note that the clinical context, patient characteristics, and local resistance patterns should be considered when deciding between monotherapy and combination therapy for CRE infections. Consulting the latest guidelines and seeking advice from an infectious disease specialist is recommended.",
                "The retrospective cohort study found that ceftolozane-tazobactam was associated with a higher clinical cure rate (83.3%) compared to polymyxins or aminoglycosides (63.6%). Ceftolozane-tazobactam also had a lower mortality rate (13.3%) compared to polymyxins or aminoglycosides (26.7%). However, it's important to note that retrospective studies have limitations and more well-designed studies are needed to confirm these findings.",
                "For severe infections caused by CRPA (Carbapenem-resistant Pseudomonas aeruginosa), the recommended antibiotic regimens include:\n\n1. Polymyxins (e.g., polymyxin B or E) in combination with an aminoglycoside (e.g., gentamicin or tobramycin).\n2. Monotherapy with a newer polymyxin (e.g., meropenem-vaborbactam or imipenem-relebactam) if susceptible.\n3. Fosfomycin in combination with an aminoglycoside or a beta-lactam antibiotic if susceptible.\n\nThese combinations aim to provide synergistic activity against CRPA and improve treatment outcomes. Always consult local guidelines and susceptibility data before making specific treatment decisions",
                "For patients with CRAB (Carbapenem-resistant Acinetobacter baumannii) and susceptible to sulbactam but resistant to other antibiotics in the setting of HAP (Healthcare-associated pneumonia) or VAP (Ventilator-associated pneumonia), the suggested treatment options may include:\n\n1. Polymyxins (e.g., colistin or polymyxin E)\n2. Amikacin or other aminoglycosides if the organism is not extensively resistant\n3. Tigecycline or other glycylcyclines\n4. Fosfomycin\n5. Ceaselessly monitoring for the emergence of resistance and adjusting therapy accordingly.\n\nIt's essential to note that the choice of antibiotic depends on the specific suscept",
                "Cefiderocol is an antibiotic with activity against gram-negative bacteria, including those commonly responsible for CRAB (community-acquired or healthcare-associated carbapenem-resistant acinetobacter baumannii) infections. Several studies have shown that cefiderocol is effective in treating CRAB infections, with success rates similar to or even superior to those of other antibiotics such as colistin and tigecycline. However, it's important to note that individual patient outcomes may vary, and the choice of antibiotic should be based on the specific infection and patient's individual circumstances. Always consult the latest clinical guidelines and literature for the most up-to-date information.",
                "Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB (Carbapenem-resistant Acinetobacter baumannii) infections. However, high-quality randomized controlled trials are needed to provide stronger evidence of its efficacy and safety. The combination therapy may improve outcomes by synergistic effects of both antibiotics against carbapenem-resistant A. baumannii.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections require specific antibiotic treatment due to their resistance to common antibiotics. Here are some general principles for antibiotic treatment:\n\n1. Identify the specific CR-GNB causing the infection through laboratory testing.\n2. Choose an antibiotic that is active against the identified CR-GNB.\n3. Consider the site of infection and the patient's overall health when selecting an antibiotic.\n4. Administer the antibiotic intravenously (IV) in severe infections or when the patient cannot take oral medication.\n5. Monitor the patient closely for adverse effects and drug interactions.\n6. Consider using combination therapy for infections caused by certain CR-GNB, such as P. aeruginosa or A. baumannii.\n7. Ensure adequate dosing",
                "For patients undergoing colorectal transplant surgery, preoperative screening typically includes colonoscopy to assess for colon cancer or precancerous lesions. For liver transplant patients, screening may include ultrasound, alpha-fetoprotein (AFP) level measurement, and hepatitis serology to assess for liver disease and liver cancer. These recommendations may vary based on individual patient risk factors and guidelines from professional organizations. Always consult with a healthcare provider for specific recommendations.",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Cephalosporin-Resistant Enterococci (ESCR-E) undergoing colorectal surgery is controversial. Some guidelines suggest considering alternative antibiotics for PAP, while others recommend using a different class of antibiotics altogether, such as aminoglycosides or glycopeptides. Ultimately, the decision should be individualized based on the specific patient's risk factors and the local antibiotic resistance patterns. Consulting with an infectious disease specialist or a colon and rectal surgeon is recommended for optimal management.",
                "The antibiotics that should be reserved for the treatment of extensively resistant bacteria (such as extensively drug-resistant Mycobacterium tuberculosis or carbapenem-resistant Enterobacteriaceae) include:\n\n1. Polymyxins (e.g., colistin)\n2. Tigecycline\n3. Amikacin (for certain types of bacteria)\n4. Bedaquiline (for M. tuberculosis)\n5. Delamanid (for M. tuberculosis)\n\nThese antibiotics should not be used routinely for targeted PAP (pre-exposure prophylaxis) in Extensively Drug-Resistant-Tuberculosis (ESCR-TB) carriers due to their potential toxicity, limited availability, and the development of resistance with overuse. Instead",
                "Recommended components for research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates include:\n\n1. Study design: Randomized controlled trials (RCTs) or observational studies.\n2. Study population: ESCR-E colonized SOT candidates.\n3. Intervention: Targeted PAP (pre-transplant antimicrobial prophylaxis) with specific antibiotics.\n4. Comparator: Standard of care or placebo.\n5. Outcomes: Primary outcome - post-transplant infections; secondary outcomes - graft function, adverse events, and microbiological outcomes.\n6. Sample size: Based on the expected effect size and power analysis.\n7. Study duration: From pre-transplantation to post-transplantation follow-up.",
                "Yes, a recommendation can be issued for targeted PAP using non-carbapenem antibiotics for patients colonized with CRE before surgery to reduce the risk of surgical site infections caused by CRE. However, the specific antibiotic choice should be based on local resistance patterns and patient factors. Consult local guidelines and infectious disease specialists for the most appropriate antibiotic selection.",
                "A good practice for screening Solid Organ Transplant (SOT) recipients for CRAB (Chronic Renal Allograft Abolition) before surgery is to assess their renal function with regular serum creatinine levels and estimated glomerular filtration rate (eGFR). Additionally, monitoring for proteinuria, hematuria, and signs of allograft dysfunction is essential. If there are concerns, a renal biopsy may be necessary to confirm CRAB. Regular follow-ups with a nephrologist are recommended for close monitoring.",
                "To investigate CRAB (Clostridioides difficile-associated diarrhea) colonization and targeted PAP (proteasome activating protein), the panel would suggest designing randomized controlled trials (RCTs) with a placebo or active comparator arm. These trials should include adequate sample size, proper study design, and standardized endpoints to assess the efficacy and safety of targeted PAP in preventing CRAB colonization. Additionally, consider using biomarkers to objectively measure CRAB colonization and response to treatment.",
                "In transplant surgery other than renal transplant, the suggested duration of post-operative positive airway pressure (PAP) varies depending on the specific type of transplant and individual patient's condition. Generally, it ranges from a few days to several weeks. For example, in liver transplant, PAP may be used for a few days to help prevent respiratory complications. In heart-lung transplant, PAP may be required for several weeks to help the lungs adjust to the new organ. It's important to consult with the transplant team for specific recommendations.",
                "The risk of Multidrug-resistant Gram-negative bacterial (MDR-GNB) infections in solid organ transplant (SOT) recipients is relatively high due to the use of immunosuppressive medications. These infections can lead to serious complications such as sepsis, organ failure, and increased mortality. Common MDR-GNB pathogens include P. aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Prevention strategies include strict infection control measures, appropriate antibiotic prophylaxis, and close monitoring for signs of infection.",
                "The suggested approach to identify FQR-E carriers before TRUSPB includes:\n\n1. Obtaining a urine culture before the procedure.\n2. Sensitivity testing for fluoroquinolones in the urine culture result.\n3. Considering alternative antibiotics for prophylaxis if FQR-E is identified.\n\nIt's important to note that the decision to test for FQR-E should be based on local prevalence and individual patient risk factors. Consult local guidelines and infectious disease specialists for specific recommendations.",
                "The specific outcome of the trial you're referring to is not readily available in a clear and short answer format, as I would need to access the study's results to provide an accurate response. However, in general, non-blinded trials may be subject to bias, and comparing ciprofloxacin PAP (prostate antimicrobial prostatease) to culture-based PAP (transrectal ultrasound-guided prostate biopsy with conventional culture) in fluoroquinolone-resistant carriers could affect the results due to potential differences in detection rates and antimicrobial efficacy. For the most accurate information, I would recommend looking up the specific study or consulting a urology or infectious disease specialist.",
                "Urinary colonization with MDR-GNB is a significant risk factor for postoperative infections in patients undergoing urologic surgery. These bacteria can cause infections during or after the procedure, leading to increased morbidity and mortality. Preoperative urine screening and appropriate antibiotic prophylaxis can help reduce the risk of these infections.",
                "A comprehensive approach to reducing surgical site infections (SSIs) includes:\n\n1. Preoperative preparation: Optimizing the patient's health, proper wound preparation, and prophylactic antibiotics.\n2. Intraoperative measures: Sterile environment, proper surgical technique, and use of sterile instruments.\n3. Postoperative care: Wound care, early ambulation, and appropriate use of drains and dressings.\n4. Infection control policies: Implementing standardized protocols, surveillance, and education for healthcare personnel.\n5. Patient selection and optimization: Addressing comorbidities and risk factors.\n6. Vaccination: Ensuring up-to-date vaccinations, especially for patients undergoing orthopedic surgery.\n7. Antimicrobial stewardship: Appropriate use of antibiotics to prevent and",
                "For standard operating procedures (SOPs) related to sampling site technique, it's important to follow these steps:\n\n1. Properly clean and prepare the sampling site.\n2. Use sterile equipment for sampling.\n3. Collect sufficient sample size.\n4. Transport samples to the lab in appropriate containers and at proper temperature.\n\nFor microbiological methods, SOPs should include:\n\n1. Properly handling and transporting samples.\n2. Using appropriate media for culturing.\n3. Incubating samples at the correct temperature and time.\n4. Identifying and reporting results according to established protocols.",
                "When choosing targeted PAP for CRE infections, consider the following factors:\n\n1. Type and site of surgery: The risk of surgical site infection (SSI) varies depending on the type and site of surgery.\n2. Patient risk factors: Factors such as age, comorbidities, and underlying conditions increase the risk of SSI.\n3. Type and susceptibility of CRE: The specific type and susceptibility of the CRE strain can influence the choice of antibiotic.\n4. Allergies and drug interactions: Patients may have allergies or drug interactions that limit the choice of antibiotics.\n5. Duration of antibiotic therapy: The length of antibiotic therapy should be based on the type and site of surgery and the susceptibility of the CRE strain.\n6. Cost and availability: The cost and availability of antibiotics should",
                "Colonization of a patient with bacteria or other pathogens that can cause infections is important to know before solid organ transplantation (SOT) because:\n\n1. Transplant recipients are at increased risk for infections due to immunosuppressive therapy.\n2. Certain bacteria or viruses can cause severe infections in the transplanted organ or other parts of the body.\n3. Antibiotic prophylaxis or other preventive measures can be taken to reduce the risk of infection in the peri-transplant period.\n4. Some infections may require delaying or even canceling the transplant procedure.\n5. Knowing the colonization status can help guide the choice of antibiotic prophylaxis and other preventive measures."
            ],
            "no additional prompt / context": [
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome: Bloodstream infections (BSI), Urinary Tract Infections (UTI), pneumonia, and intra-abdominal infections (IAI). The studies referred to in the text are described in Table 3.\n\n        For BSI, the MERINO trial compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant Escherichia coli and K. pneumoniae. The primary outcome was 30-day mortality, and the study did not prove the non-inferiority of piperacillin-tazobactam.\n\n        Local guidelines should address the empirical treatment phase, and the Infectious Dise",
                "The retrospective observational studies comparing carbapenems with non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, for the treatment of 3GCephRE infections did not find any statistically significant differences in clinical outcomes between the two groups. However, the studies were at high risk of bias due to the lack of adjustment for confounding factors and the potential for selection bias. The overall certainty of the evidence was judged as very low due to the limitations of the observational studies.",
                "The studies evaluating cephamycins (cefmetazole or flomoxef) versus carbapenems for the treatment of 3GCephRE BSI showed conflicting results. In the largest study, no association was found between targeted flomoxel therapy and mortality, but when flomoxel's MIC were elevated within the susceptible range, flomoxel was associated with mortality compared with carbapenems. Another small study showed higher mortality with targeted flomoxel compared with carbapenems, but most patients did not receive in vitro covering therapy in the first 5 days and appropriate adjustment was not possible. The overall certainty of the evidence for a possible advantage of carbapenems over cephamycins was very low.",
                "None of the studies found statistically significant differences between cephamycins and cefepime and carbapenems for the treatment of pyelonephritis caused by 3GCephRE, providing low-certainty evidence for their use.",
                "The retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated UTI found no statistically significant differences between the two groups in terms of mortality, clinical failure, or relapse. However, most of these studies were at high risk of bias, and the sample sizes were small, making it difficult to draw definitive conclusions. Additionally, the studies assessed a variety of non-carbapenem antibiotics, including BLBIs, quinolones, and aminoglycosides, making it challenging to make direct comparisons between specific antibiotics. Overall, the evidence from these studies supports the use of non-carbapenem antibiotics as carbapenem-sparing alternatives for the treatment of complicated UTI caused by 3GCephRE, but the certainty of this evidence is moderate to low due to",
                "The context above does not provide specific information about the findings of RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE. However, it mentions that most new antibiotic approval RCTs were syndrome-based and the subgroups of patients with 3GCephRE infections were small. It also highlights the need for more RCTs to assess patients with infections due to 3GCephRE and CR-GNB.",
                "Based on the small RCT (Tango-II) study, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics. However, it is important to note that the evidence base is still limited and more studies are needed to confirm these findings.",
                "The level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is moderate. Several studies have shown better microbiological cure and clinical success with aminoglycosides compared to tigecycline for cUTI. However, there is insufficient evidence for other comparisons and other sources of infection. It is important to note that the use of aminoglycosides carries a risk for nephrotoxicity, so shorter durations of therapy are recommended.",
                "Based on the context provided, there is currently insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections. The CARE-RCT study, which was designed to test the efficacy of plazomicin against colistin, was suspended after 2 years due to enrolment difficulties. The available results showed that all-cause mortality at 28 days was lower in patients treated with plazomicin combination therapy compared with colistin combination therapy, but the sample size was small and the study was not powered to draw definitive conclusions. Therefore, more research is needed to determine the comparative efficacy and safety of plazomicin and colistin for the treatment of CRE infections.",
                "Based on the evidence provided in the context, there is low-certainty evidence for no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. The AIDA and OVERCOME RCTs did not show significant differences in clinical failure or mortality overall and among patients with CRAB infections. However, a post-hoc analysis of the AIDA trial showed no benefit to the combination over colistin among patients with colistin-resistant CRAB. Several observational studies showed conflicting results regarding the association between colistin-carbapenem combination therapy and survival or clinical cure compared with colistin monotherapy. A retrospective Italian cohort study suggested an association between high-dose extended-infusion meropenem-polymy",
                "Based on the available evidence, there is no clear answer to whether cefiderocol monotherapy or combination therapy is more effective in the treatment of CRE infections. The RESTORE-IMI 1 trial, which is the only RCT that has tested cefiderocol against CR-GNB, did not show any significant difference in clinical or microbiological outcomes between cefiderocol monotherapy and a polymyxin-based combination. However, mortality was higher in the cefiderocol arm, which may be due to the fact that most patients in the cefiderocol group had MBL-producing CR-GNB infections. A subgroup analysis of patients with MBL-producing CR-GNB infections showed statistically non-significant higher cure and microbiological eradication rates for cefiderocol, but mortality was not shown and the analysis",
                "The retrospective cohort study compared the clinical care and nephrotoxicity of ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections, mostly pneumonia. The study found that clinical care was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam. However, the study had a high risk of bias due to unclear patient selection, lack of adjustment for baseline differences between groups, and no data on carbapenem resistance. Overall, the",
                "Based on the context provided, the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combinations can be recommended or against.",
                "For patients with CRAB susceptible to sulbactam and HAP/VAP, the suggested treatment is ampicillin-sublactam (conditional recommendation, low certainty of evidence).",
                "Based on the available evidence, the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections is not clear. The CREDIBLE RCT showed no advantage of cefiderocol over BAT in terms of clinical or microbiological eradication in patients with CRAB infections. In the APEKS-NP RCT, similar mortality, clinical, and microbiological outcomes were documented for cefiderocol and high-dose extended-infusion meropenem in patients with pneumonia and A. baumannini species with meropenem MIC >8 mg/mL. Given the limited information available to date, the evidence for or against the use of cefiderocol for CRAB infections is low-certainty.",
                "Several observational studies have assessed the combination of polymyxins and carbapenems for CRAB infections. Some of these studies showed a significant association between the use of the combination and survival or clinical cure, while others did not. However, many of these studies included patients treated with a polymyxin-carbapenem combination in a larger group of patients treated with different combination therapies. From these studies, the effects of a specific combination regimen cannot be assessed. Overall, the high-certainty evidence from RCTs, including the AIDA and OVERCOME trials, does not support the use of polymyxin-carbapenem combination therapy for CRAB infections.",
                "1. The choice of antibiotic treatment for CR-GNB infections depends on the severity of the infection and the availability of antibiotics.\n        2. In severe infections caused by DTR-CRPA, ceftolozane-tazobactam is suggested as a treatment option if active against the specific strain (conditional recommendation, very low certainty of evidence).\n        3. For non-severe or low-risk CR-GNB infections, it is considered good clinical practice to use old antibiotics that are active against the specific pathogen based on local epidemiology and antibiotic stewardship considerations.\n        4. Combination therapies are less strongly recommended due to limited evidence on clinical outcomes.\n        5. Antibiotics should be tailored to the specific infection source, such as piperacillin-tazobact",
                "Based on the context provided, it is suggested that patients undergoing colorectal and liver transplant surgery be screened for Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before the surgery, according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery, according to the local epidemiology (ungraded good practice statement). The implementation of screening procedures should follow a careful assessment of local prevalence of ESCR-E colonization and infection among patients admitted or transferred to the surgical wards, and the choice of targeted versus universal screening should be based on the local work organization and integrated within diagnostic and antibiotic stewardship guidance. Changes in screening and PAP policies should be based on local epidemi",
                "Based on the context provided, it is recommended to use targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery (conditional recommendation for use, low certainty of evidence). The choice of antibiotics for targeted PAP should follow antimicrobial stewardship considerations, including limiting the use of carbapenems if other options are available and avoiding the routine use of reserve antibiotics.",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. The use of carbapenems should also be limited if other antibiotic options are available against ESCR-E.",
                "1. Postsurgical monitoring of antibiotic resistance: This includes monitoring for CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n        2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n        3. Investigating the mechanisms of resistance of newly isolated MDR-GNB detected after surgery.\n        4. Considering the local burden of ESCR-E and patient-related risk factors for carrier status, such as previous ESCR-E infections, recent use of broad-spectrum antibiotics, previous hospital or long-term care facility admission or prolonged stay, ICU stay, or mechanical ventilation.\n        5. Monitoring for same-strain colonization and infection relatedness.",
                "Based on the current evidence, a conditional recommendation is made for implementing rectal screening to identify CRE carriers before surgery and considering targeted PAP for those who test positive, according to local epidemiology and antimicrobial stewardship principles (low certainty of evidence). However, there is a lack of data on the effectiveness, applicability, and safety of targeted PAP in CRE carriers undergoing SOT and other high-risk surgical procedures. Therefore, clinical trials are recommended to assess the impact of CRE rectal screening and targeted PAP in this population.\n\n        Regarding the use of targeted PAP for patients colonized with carbapenem-resistant Acinetobacter baumannii (CRAB) before surgery, a conditional recommendation is made for implementing rectal screening to identify CRAB carriers before liver transplant surgery and considering targeted PAP for those",
                "It might be a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology (ungraded good practice statement). Any change in screening procedures should follow a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards, considering a prevalence >=10% as a cut-off for implementation evaluation. The choice of targeted versus universal screening should be based on the local work organization and integrated within antibiotic and diagnostic stewardship guidance. The knowledge of the colonization status of the patient before SOT is essential for early implementation of infection control procedures.",
                "The panel suggests designing clinical trials to assess the impact of CRAB rectal screening in high-risk surgeries. Additionally, trials of targeted PAP in CRAB carriers undergoing SOT and other high-risk surgical procedures should be designed to evaluate the effectiveness, applicability, and safety of the intervention following antimicrobial stewardship principles. These trials should consider rectal culture results, the limited number of options for the treatment of CRE infections, and resistance monitoring through detection of MDR-CNB carriage after surgery and to detect emerging resistance to the regimens used for targeted PAP.",
                "Based on the current recommendations from international societies such as the Infectious Diseases Society of America, American Society of Health-System Pharmacists, Surgical Infection Society, and Society for Healthcare Epidemiology of America, PAP should be discontinued within 24 hours after surgery in patients colonized with MDR-GNB. However, for transplant surgery other than renal transplant, the extension of PAP duration to 48-72 hours may be considered according to the type of transplant as a good practice statement. This recommendation aligns with current guidelines and is based on the principle of minimizing the risks associated with prolonged antibiotic administration. However, further research is needed to investigate the clinical impact of shorter versus longer PAP in patients undergoing transplant surgery.",
                "The risk of MDR-GNB infections in solid organ transplant (SOT) recipients varies depending on the type of organ transplanted and the geographic area. SSIs are a common issue and may occur in 3% to 53% of SOT recipients, with highest rates observed for intestinal, liver, and pancreas transplantation. LTR recipients are at risk of developing intra-abdominal infections, especially in the early post-LT period, with the risk of ESCR-E and CRKP infections ranging from 6% to 13% and 3% and 10%, respectively. ESCR-E infections are common, accounting for up to 75% of MDR-GNB isolates in SOT recipients. Among nonfermenters, rates of CRAB and MDR PA",
                "Based on the evidence reviewed, it is suggested that rectal screening be implemented to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence). This recommendation is supported by studies showing an association between FQR-E colonization and increased rates of post-TRUSPB infectious complications. Additionally, targeted PAP is recommended for patients who are colonized with FQR-E before TRUSPB (conditional recommendation, moderate certainty of evidence). This approach is supported by studies suggesting that the use of targeted PAP, such as entrapment, cefoxitin, and fosfomycin, may reduce the incidence of BSIs in FQR-E carriers undergoing TRUSPB. However, it is important to note that the evidence is limited by a high variability in the regimens used and the short follow-up to assess",
                "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for patients receiving culture-based PAP versus ciprofloxacin PAP. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers. However, the trial did not identify an optimal targeted PAP for FQR-E carriers undergoing TRUSPB. Further high-quality trials are recommended to assess the efficacy of specific PAP regimens in FQR-E carriers and to investigate the impact of colonization with MDR-GNB other than FQR-E on post-TRUSPB infections.",
                "Based on the context provided, there is limited evidence on the impact of targeted PAP on infectious complications following urologic surgery in MDR-GNB carriers. However, there is evidence suggesting that urinary colonization with MDR-GNB may increase the risk of postoperative infections in patients undergoing urologic surgery. Patients undergoing urologic surgery often have risk factors for MDR-GNB acquisition, such as previous surgical procedures, permanent bladder catheters, and double J stents.\n\n        A small, prospective single-centre study included 75 patients undergoing urologic surgery and receiving PAP based on the results of urine cultures. Sixteen (22%) ESCR-E carriers received targeted PAP mainly with aminoglycosides, cefoxitin, and imipenem. Eleven",
                "The comprehensive approach required to reduce surgical site infections (SSIs) involves a combination of antibiotic-based interventions and best surgical practices. Antibiotic-based interventions include targeted prophylaxis against multidrug-resistant gram-negative bacteria (MDR-GNB) and optimization of antibiotic stewardship initiatives. Best surgical practices include minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities. It is also important to investigate the clinical impact of shorter versus longer antibiotic prophylaxis durations in patients undergoing transplant surgery. Additionally, efforts should be made to analyze the potential for resistance selection and side effects when investigating antibiotic combinations for MDR-GNB. Other antibiotic-based interventions, such as decolonization and selective",
                "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
                "1. Local prevalence of CRE colonization and infection: A careful assessment of the local epidemiology is essential before implementing targeted PAP for CRE infections. A prevalence of >=10% is considered a reasonable cut-off for implementation evaluation.\n        2. Evidence-based screening protocols: Any change in procedures should consider evidence-based screening protocols, including rectal culture and screening of different body sites.\n        3. Limited options for the treatment of CRE infections: The choice of targeted PAP should take into consideration the limited number of options that are available for the treatment of CRE infections. Avoiding novel compounds that may be required for the treatment of postsurgical infections is important.\n        4. Resistance monitoring: Resistance monitoring should be performed through detection of MDR-CNB carriage after surgery and to detect emerging resistance to the regimens used for",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) because the knowledge of this information is essential for the early implementation of infection control procedures. This can help reduce the risk of intrahospital and community spreading of multidrug-resistant bacteria (MDR-GNB), such as carbapenem-resistant Enterobacterales (CRE), extensively drug-resistant Pseudomonas aeruginosa (XDRPA), and carbapenem-resistant Acinetobacter baumannii (CRAB), which are associated with higher mortality rates compared with their susceptible counterparts. By identifying MDR-GNB carriers before SOT, healthcare providers can take appropriate measures to prevent the spread of these bacteria and minimize the risk of post-transplant infections. Additionally, targeted preoperative antimicrobial prophyl"
            ],
            "additional prompt / context": [
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome: Bloodstream infections (BSI), Urinary Tract Infections (UTI), pneumonia, and intra-abdominal infections (IAI). The studies referred to in the text are described in Table 3. For BSI, the MERINO trial compared piperacillin-tazobactam with meropenem, but it did not prove the non-inferiority of piperacillin-tazobactam. Local guidelines should address the empirical treatment phase, and alternatives to carbapenems and the new BLBII are considered in our guidelines, stratifying patients by sepsis severity. Combination therapies are less strongly recommended in our guidelines due to the limited certainty of the evidence. Antibiotics, both old and new",
                "None of the retrospective observational studies found statistically significant differences in mortality and other outcomes between carbapenems and non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, for the treatment of 3GCephRE infections. However, the overall certainty of the evidence was judged as low for low-risk infections and very low for high-risk infections due to the limitations of the observational data, such as small sample sizes, lack of adjustment for indication bias, severity of infection, different bacteria and ESBL types, sources of infection, and interaction between types of bacteria and source of infection, and different susceptibility testing methods and definitions of 3GCephRE.",
                "The studies evaluating cephamycins (cefmetazole or flomoxef) versus carbapenems for the treatment of 3GCephRE BSI showed conflicting results. In some studies, no association was found between targeted cephamycin therapy and mortality. However, when cephamycin's MIC were elevated within the susceptible range, cephamycins were associated with mortality compared with carbapenems. The overall certainty of the evidence for a possible advantage of carbapenems over cephamycins was very low.",
                "None of the studies found statistically significant differences between cephamycins and cefepime and carbapenems for the treatment of pyelonephritis caused by 3GCephRE, providing low-certainty evidence for their use.",
                "The retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated UTI found no statistically significant differences between the two groups in terms of mortality, clinical failure, or relapse. However, most studies were at high risk of bias and the sample sizes were small, making it difficult to draw definitive conclusions. The evidence for the use of non-carbapenem antibiotics as carbapenem-sparing regimens in the treatment of complicated UTI is considered to be very low to moderate-risk.",
                "The context above mentions that there is a lack of high-quality evidence from RCTs evaluating various antibiotics for the treatment of IAI caused by 3GCephRE. Therefore, it is not possible to provide a definitive answer to the question about the findings of such RCTs. However, it is mentioned that most antibiotic approval trials were syndrome-based and included only a few patients with MDR bacteria for which these antibiotics were developed. Therefore, more RCTs are needed to assess the efficacy and safety of different antibiotics for the treatment of IAI caused by 3GCephRE.",
                "Based on the small RCT (Tango-II) study, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics.",
                "The level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is moderate, based on studies showing better microbiological cure and survival in some patient populations, but with insufficient evidence for other comparisons and sources of infection.",
                "Based on the context provided, there is currently insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections. The CARE-RCT study, which was designed to test the efficacy of plazomicin against colistin, was suspended after 2 years due to enrolment difficulties, and the available results showed no significant difference in all-cause mortality at 28 days between the two treatments.",
                "Based on the evidence provided in the context, there is low-certainty evidence for no significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. However, some studies suggest a potential benefit of high-dose extended-infusion meropenem-polymyxin combination therapy over polymyxin monotherapy. Double-carbapenem combination therapy shows promising results but requires further evaluation due to limited evidence.",
                "Based on the available evidence, there is no clear advantage of cefiderocol monotherapy over combination therapy in the treatment of CRE infections. The RESTORE-IMI 1 trial, which compared cefiderocol with imipenem-relebactam, did not show any significant difference in clinical or microbiological outcomes between the two groups. However, a subgroup analysis of patients with MBL-producing CR-GNB infections showed a trend towards higher cure and microbiological eradication rates for cefiderocol, but this did not translate into a survival benefit. Given the limited data available, it is currently unclear whether cefiderocol monotherapy or combination therapy is more effective in the treatment of CRE infections.\n\n        It is important to note that the evidence for using any specific antibiotic or treatment regimen for CRE infections is limited,",
                "The retrospective cohort study reported higher clinical care and lower nephrotoxicity with ceftolozane-tazobactam compared with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections. However, the study had a high risk of bias due to unclear patient selection, lack of adjustment for baseline differences between groups, and no data on carbapenem resistance.",
                "The recommendation for treating severe inctions caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combinations can be recommended or against.",
                "For patients with CRAB susceptible to sulbactam and HAP/VAP, the suggested treatment is ampicillin-sublactam.",
                "Based on the available evidence, the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections is not clearly established. The CREDIBLE RCT showed no advantage of cefiderocol over BAT in terms of clinical or microbiological eradication in patients with CRAB infections. Additionally, in the APEKS-NP RCT, there were similar mortality, clinical, and microbiological outcomes for cefiderocol and high-dose extended-infusion meropenem in patients with pneumonia and A. baumannini species with meropenem MIC >8 mg/mL. Given the limited information available to date, the evidence for cefiderocol treatment of CRAB infections is of low certainty.",
                "Several observational studies have assessed the combination of polymyxins and carbapenems for CRAB infections, showing a significant association between use of the combination and survival or clinical cure in some studies [198, 235, 247]. However, other studies did not show a benefit [199, 244]. Many of these studies included patients treated with a polymyxin-carbapenem combination in a larger group of patients treated with different combination therapies, making it difficult to assess the effects of a specific combination regimen. Overall, the evidence from observational studies is inconclusive and requires further evaluation.",
                "1. The choice of antibiotic for CR-GNB infections depends on the severity of the infection and the availability of antibiotics.\n2. In severe infections, ceftolozane-tazobactam is suggested as a conditional recommendation for use, but insufficient evidence is available for other new antibiotics like imipenem-relebactam, cefiderocol, and ceftazidime-avibactam.\n3. In non-severe or low-risk CR-GNB infections, it is good clinical practice to use old antibiotics that are active against CR-GNB based on local epidemiology and individual patient considerations.\n4. Antibiotic stewardship is crucial to ensure the appropriate use of antibiotics, including carbapenems and the new BLBLI.\n5. Cost",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epidemiology (ungraded good practice statement). The implementation of screening procedures should follow a careful assessment of local prevalence of ESCR-E colonization and infection, and the choice of targeted versus universal screening should be based on local work organization and integrated within diagnostic and antibiotic stewardship guidance. Changes in screening and PAP policies should be based on local epidemiology, microbiological capacity, locally available financial resources, and patient's risk",
                "We conditionally recommend targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery (conditional recommendation for use, low certainty of evidence).\n        \n        It is important to consider antimicrobial stewardship when choosing antibiotics for targeted PAP in ESCR-E carriers. Carbapenems should be limited if other antibiotic options are available against ESCR-E, and reserve antibiotics should not be routinely used for targeted PAP (Nutman et al. [41], Logre et al. [32]).",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. The use of carbapenems should also be limited if other antibiotic options are available against ESCR-E.",
                "1. Postsurgical monitoring of antibiotic resistance, specifically CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n        2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n        3. Considering the local burden of ESCR-E and patient-related risk factors for carrier status, such as previous ESCR-E infections, recent use of broad-spectrum antibiotics, previous hospital or long-term care facility admission or prolonged stay, ICU stay, or mechanical ventilation.\n        4. Postsurgical monitoring of resistance development to the antibiotics used for targeted regimens.\n        5. Investigating same-strain colonization and infection relatedness, as well as the mechanisms of",
                "Based on the current evidence, a conditional recommendation for targeted PAP in patients colonized with CRE undergoing high-risk surgical procedures, such as liver or kidney transplantation, is suggested (low certainty of evidence). However, the choice of targeted PAP should consider the limited number of options available for the treatment of CRE infections and avoid novel compounds that may be required for the treatment of postsurgical infections. Resistance monitoring should also be performed to detect emerging resistance to the regimens used for targeted PAP.",
                "It might be a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology. Any change in screening procedures should follow a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards, considering a prevalence >=10% as a cut-off for implementation evaluation. The choice of targeted versus universal screening should be based on the local work organization and integrated within antibiotic and diagnostic stewardship guidance. The knowledge of the colonization status of the patient before SOT is essential for early implementation of infection control procedures.",
                "The panel suggests designing clinical trials to assess the impact of CRAB rectal screening in high-risk surgeries and trials of targeted PAP in CRAB carriers undergoing SOT and other high-risk surgical procedures to evaluate the effectiveness, applicability, and safety of the intervention following antimicrobial stewardship principles. These trials should consider rectal culture results, the limited number of options for treating CRE infections, and resistance monitoring.",
                "Based on expert opinion, the suggested duration of PAP in transplant surgery other than renal transplant is 48-72 hours. However, this recommendation is not strongly supported by evidence and should be considered on a case-by-case basis.",
                "The risk of MDR-GNB infections in SOT recipients varies depending on the type of organ transplanted and the geographic area. SSIs are a common issue and may occur in 3% to 53% of SOT recipients, with highest rates observed for intestinal, liver, and pancreas transplantation. LTR recipients are at risk of developing intra-abdominal infections, especially in the early post-LT period. The risk of ESCR-E and CRKP infections ranges from 6% to 13% and 3% and 10%, respectively. ESCR-E infections are common, accounting for up to 75% of MDR-GNB isolates in SOT recipients. Among nonfermenters, rates of CRAB and MDR PA up to 63% and",
                "Based on the evidence reviewed, it is recommended to perform rectal screening to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
                "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for patients receiving culture-based PAP versus ciprofloxacin PAP. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers. However, the study did not identify an optimal targeted PAP for FQR-E carriers undergoing TRUSPB.",
                "There is limited evidence suggesting that urinary colonization with MDR-GNB is associated with an increased risk of postoperative infections in patients undergoing urologic surgery. However, studies comparing postoperative infections in MDR-GNB urinary carriers versus noncarriers are lacking. A small prospective study showed that ESCR-E carriers who received targeted PAP based on urine cultures had a higher rate of postoperative infections compared to noncarriers (11% vs. 5%). Additionally, 80% of postoperative infections in ESCR-E carriers were caused by the same colonizing strain, compared to 9% in noncarriers. However, more well-designed studies are needed to confirm this association and to investigate the impact of targeted PAP on microbiological, epidemiological, and clinical outcomes.",
                "The comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted preoperative antibiotic prophylaxis (PAP) and decolonization, and best surgical practices. These practices include minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, and managing patient comorbidities. Additionally, heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach are essential to effectively target SSIs. Investigating the impact of carrier status for MDR-GNB other than ESCR-E, CRE, and CRAB, and exploring the potential of other antibiotic-based interventions, such as SDD and oral antibiotics, should also be considered. Metagenomic studies assessing the effect of antibi",
                "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
                "1. Local prevalence of CRE colonization and infection among patients admitted or transferred to the surgical wards.\n2. Implementation of evidence-based screening protocols, including rectal screening.\n3. The limited number of options available for the treatment of CRE infections, avoiding novel compounds that may be required for the treatment of postsurgical infections.\n4. Resistance monitoring through detection of MDR-GNB carriage after surgery and investigation of short- and long-term postsurgical colonization.\n5. Antimicrobial stewardship considerations, including limiting the use of carbapenems and reserve antibiotics.\n6. Clinical trials designed considering rectal culture results and the choice of targeted PAP taking into account the limited options for the treatment of CRE infections.",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) because this information is essential for the early implementation of infection control procedures. This can help reduce the risk of intrahospital and community spreading of multidrug-resistant bacteria (MDR-GNB), which are associated with higher mortality compared with their susceptible counterparts. The choice of targeted versus universal screening for MDR-GNB should be based on the local work organization and integrated within antibiotic and diagnostic stewardship guidance. The knowledge of the colonization status before SOT is also useful to inform contact precaution in SOT candidates and may be taken into consideration when treating postoperative infections."
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.05825995970071625,
                    "2_gram": 0.1086544286689707,
                    "3_gram": 0.08245166342278999,
                    "4_gram": 0.05762861075592003
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.15950488055112882,
                        "recall": 0.49337001319598367,
                        "fmeasure": 0.2321360593614503
                    },
                    "rouge_L": {
                        "precision": 0.10627614184215597,
                        "recall": 0.3464475984983581,
                        "fmeasure": 0.15717844070388162
                    }
                },
                "METEOR": 0.23319947465371624,
                "BERTScore": {
                    "Precision": -0.05,
                    "Recall": 0.188,
                    "F1_measure": 0.066
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.07727498139803828,
                    "2_gram": 0.14304701539742642,
                    "3_gram": 0.11089397247759285,
                    "4_gram": 0.07784888694697885
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20930895927064935,
                        "recall": 0.48220175693478623,
                        "fmeasure": 0.2773765627831704
                    },
                    "rouge_L": {
                        "precision": 0.14217141211985482,
                        "recall": 0.3310637194145358,
                        "fmeasure": 0.18884870776000837
                    }
                },
                "METEOR": 0.2528374413158506,
                "BERTScore": {
                    "Precision": 0.031,
                    "Recall": 0.229,
                    "F1_measure": 0.129
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.0879136623606003,
                    "2_gram": 0.17966153297024073,
                    "3_gram": 0.17982006204802686,
                    "4_gram": 0.14991883559196342
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.334827943181848,
                        "recall": 0.7858578736443422,
                        "fmeasure": 0.43752319360556813
                    },
                    "rouge_L": {
                        "precision": 0.27035916770314694,
                        "recall": 0.6393108057562524,
                        "fmeasure": 0.35388413899040233
                    }
                },
                "METEOR": 0.4972269845461388,
                "BERTScore": {
                    "Precision": 0.206,
                    "Recall": 0.542,
                    "F1_measure": 0.367
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.11079451793033547,
                    "2_gram": 0.21366913353734632,
                    "3_gram": 0.20917207454396583,
                    "4_gram": 0.17335213400785593
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3878250831120358,
                        "recall": 0.7344336587642933,
                        "fmeasure": 0.47441397265004054
                    },
                    "rouge_L": {
                        "precision": 0.3184547802784883,
                        "recall": 0.6039789997961985,
                        "fmeasure": 0.39021944049514684
                    }
                },
                "METEOR": 0.48916009852494674,
                "BERTScore": {
                    "Precision": 0.292,
                    "Recall": 0.542,
                    "F1_measure": 0.412
                }
            }
        }
    }
]